Search

Your search keyword '"Bradic N"' showing total 36 results
Start Over Author "Bradic N"
36 results on '"Bradic N"'

1. Management of Challenging Cardiopulmonary Bypass Separation

Author

Monaco, Fabrizio, Di Prima, Ambra Licia, Kim, Jun Hyun, Plamondon, Marie-Jo, Yavorovskiy, Andrey, Likhvantsev, Valery, Lomivorotov, Vladimir, Hajjar, Ludhmila Abrahão, Landoni, Giovanni, Riha, H., Farag, A.M.G.A., Gazivoda, G., Silva, F.S., Lei, C., Bradic, N., El-Tahan, M.R., Bukamal, N.A.R., Sun, L., and Wang, C.Y.

Published
2020
Full Text
View/download PDF

2. Correction: Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies (Critical Care, (2023), 27, 1, (3), 10.1186/s13054-022-04294-5)

Author

McNicholas B. A., Mcnicholas, B, Rezoagli, E, Simpkin, A, Khanna, S, Suen, J, Yeung, P, Brodie, D, Bassi, G, Pham, T, Bellani, G, Fraser, J, Laffey, J, Al-Dabbous, T, Alfoudri, H, Shamsah, M, Alhadad, Q, Hanan, M, Elapavaluru, S, Berg, A, Horn, C, Abdelhalim, A, Amer, A, Elnaggar, C, Hassan, A, Abdelaziz, A, Abdelhalim, M, Orabi, Y, Alaraji, Z, Muhaisen, M, Almasri, L, Mustafa, D, Hamdan, S, Al-Saba'a, Y, Dalloul, Z, Alkahlout, M, Jaber, H, Aldabbourosama, O, Hussein, A, Emad, Z, Khaled, S, Mohamed, N, Hassanin, E, Hamdi, A, Ragab, A, Azizeldin, M, Mayasi, Y, Schroll, S, Meyer, D, Velazco, J, Ploskanych, L, Fikes, W, Bagewadi, R, Dao, M, White, H, Laviena, A, Ehlers, A, Shalabi-McGuire, M, Witt, T, Grazioli, L, Lorini, L, Grandin, E, Nunez, J, Reyes, T, O'Briain, D, Hunter, S, Ramanan, M, Affleck, J, Veerendra, H, Rai, S, Russell-Brown, J, Nourse, M, Joseph, M, Mitchell, B, Tenzer, M, Abe, R, Cho, H, Jeong, I, Rahman, N, Kakar, V, Sun, H, Hanley, A, Brozzi, N, Mehkri, O, Krishnan, S, Duggal, A, Houltham, S, Graf, J, Diaz, R, Orrego, R, Delgado, C, Gonzalez, J, Sanchez, M, Piagnerelli, M, Sarrazin, J, Zabert, G, Espinosa, L, Delgado, P, Delgado, V, Rincon, D, Yanten, A, Duque, M, Abouelmagd, K, Elhazmi, A, Al-Hudaib, A, Javidfar, J, Callahan, M, Dong, A, D'Orleans, C, Taufik, M, Wardoyo, E, Gunawan, M, Trisnaningrum, N, Irawany, V, Rayhan, M, Panigada, M, Pesenti, A, Zanella, A, Grasselli, G, Colombo, S, Martinet, C, Florio, G, Antonelli, M, Carelli, S, Grieco, D, Asaki, M, Hoshino, K, Salazar, L, Monsalve, M, Cosgrave, D, Atif, M, Qutishat, F, Laffey, C, Van Der Walt, M, Mccaffrey, J, Bone, A, Hakeem, Y, Winearls, J, Tallott, M, Thomson, D, Joubert, I, Arnold-Day, C, Piercy, J, van Zyl Smit, R, Miller, M, Seymour, L, van Heyningen, F, Teyangesikayi, G, Fredericks, D, Hssain, A, Aliudin, J, Alqahtani, A, Mohamed, K, Mohamed, A, Tan, D, Villanueva, J, Zaqout, A, Kurtzman, E, Ademi, A, Dobrita, A, El Aoudi, K, Segura, J, Giwangkancana, G, Ohshimo, S, Osatnik, J, Joosten, A, Torres, A, Yang, M, Motos, A, Luna, C, Arancibia, F, Williams, V, Noel, A, Luque, N, Fantini, M, Garcia, R, Alvarez, E, Greti, A, Ceccato, A, Sanchez, A, Vazquez, A, Roche-Campo, F, Franch-Llasat, D, Tuazon, D, Amato, M, Cassimiro, L, Pola, F, Ribeiro, F, Fonseca, G, Dalton, H, Desai, M, Osborn, E, Deeb, H, Arcadipane, A, Martucci, G, Panarello, G, Vitiello, S, Bianco, C, Occhipinti, G, Rossetti, M, Cuffaro, R, Cho, S, Whitman, G, El Sayed, M, Mokhtar, W, El-Shenawy, E, Shimizu, H, Moriyama, N, Kim, J, Kitamura, N, Gebauer, J, Yokoyama, T, Al-Fares, A, Buabbas, S, Alamad, E, Alawadhi, F, Alawadi, K, Khalefa, M, Al Ajeel, N, Aly, M, Al-Saleh, A, Naanouh, A, Elshourbgy, A, Gad, M, Elrazaz, R, Khadadah, I, Almumin, A, Altarakma, H, Albannay, H, Alsaleh, M, Radwan, M, Saadallah, I, Tanaka, H, Hashimoto, S, Yamazaki, M, Oh, T, Epler, M, Forney, C, Kruse, L, Feister, J, Williamson, J, Grobengieser, K, Gnall, E, Golden, S, Caroline, M, Shapiro, T, Karaj, C, Thome, L, Sher, L, Vanderland, M, Welch, M, Mcdermott, S, Brain, M, Mineall, S, Unwin, M, Chen, L, Trezise, T, Mckeon, L, Kimura, D, Brazzi, L, Sales, G, Montrucchio, G, Ogston, T, Nagpal, D, Fischer, K, Lorusso, R, van Bussell, B, De Piero, M, Mariani, S, Rangappa, R, Shetty, R, Rai, P, Ganesan, A, Esperatti, M, Fuentes, N, Gonzalez, M, Carton, E, Sen, A, Palacios, A, Rainey, D, Samoukoviv, G, Campisi, J, Durham, L, Neumann, E, Seefeldt, C, Falcucci, O, Emmrich, A, Guy, J, Johns, C, Potzner, K, Zimmermann, C, Espinal, A, Buchtele, N, Schwameis, M, Korhnfehl, A, Brock, R, Staudinger, T, Stecher, S, Barnikel, M, Anton, S, Pawlikowski, A, Zaaqoq, A, Galloway, L, Merley, C, Nichol, A, Csete, M, Quesada, L, Saba, I, Kasugai, D, Hiraiwa, H, Tanaka, T, Marwali, E, Purnama, Y, Dewayanti, S, Ardiyan, Juzar, D, Siagian, D, Chen, Y, Ogino, M, Nasa, P, Matthew, C, Majeed, N, Ratsep, I, Post, A, Sillaots, P, Krund, A, Lehiste, M, Lepik, T, Manetta, F, Mihelis, E, Sarmiento, I, Narasimhan, M, Varrone, M, Komats, M, Garcia-Diaz, J, Harmon, C, Satyapriya, S, Bhatt, A, Mokadam, N, Uribe, A, Gonzalez, A, Shi, H, Mckeown, J, Pasek, J, Fiorda, J, Echeverria, M, Moreno, R, Zakhary, B, Cavana, M, Cucino, A, Foti, G, Giani, M, Fumagalli, B, Chiumello, D, Castagna, V, Dell'Amore, A, Navalesi, P, Shum, H, Vuysteke, A, Usman, A, Acker, A, Smood, B, Mergler, B, Sertic, F, Subramanian, M, Sperry, A, Rizer, N, Burhan, E, Rasmin, M, Akmal, E, Sitompul, F, Lolong, N, Naivedh, B, Erickson, S, Barrett, P, Dean, D, Daugherty, J, Loforte, A, Khan, I, Quraishi, M, Desantis, O, So, D, Kandamby, D, Mandei, J, Natanael, H, Yudhalantang, E, Lantang, A, Wijaya, S, Jung, A, Ng, G, Ng, W, Ng, P, Fang, S, Tabah, A, Ratcliffe, M, Duroux, M, Alajeeli, A, Tarhabat, A, Adachi, S, Nakao, S, Blanco, P, Prieto, A, Sanchez, J, Nicholson, M, Butt, W, Serratore, A, Delzoppo, C, Janin, P, Yarad, E, Totaro, R, Coles, J, Pujo, B, Balk, R, Vissing, A, Kapania, E, Hays, J, Fox, S, Yantosh, G, Mishin, P, Yuliarto, S, Santoso, K, Djajalaksana, S, Fatoni, A, Fukuda, M, Liu, K, Pelosi, P, Battaglini, D, Jimenez, J, Bastos, D, Gaiao, S, Rusmawatiningtyas, D, Cho, Y, Lee, S, Kawasaki, T, Munshi, L, Sakiyalak, P, Nitayavardhana, P, Elagili, M, Salem, T, Seitz, T, Arora, R, Kent, D, Marino, D, Parwar, S, Cheng, A, Miller, J, Fujitani, S, Shimizu, N, Madhok, J, Owyang, C, Buscher, H, Reynolds, C, Maasikas, O, Aleksanbeljantsev, Mihnovits, V, Akimoto, T, Aizawa, M, Horibe, K, Onodera, R, Hodgson, C, Burrell, A, Young, M, George, T, Shekar, K, Mcguinness, N, Irvine, L, Flynn, B, Endo, T, Sugiyama, K, Shimizu, K, Fan, E, Exconde, K, Ichiba, S, Binnawara, M, Lussier, L, Lotz, G, Malfertheiner, M, Maier, L, Dreier, E, Kusumastuti, N, Mccloskey, C, Dabaliz, A, Elshazly, T, Smith, J, Szuldrzynski, K, Bielanski, P, Wille, K, Murthy, S, Parhar, K, Fiest, K, Codan, C, Shahid, A, Fayed, M, Evans, T, Gutierrez, A, Song, T, Rose, R, Bennett, S, Richardson, D, Peek, G, Arora, L, Rappapport, K, Rudolph, K, Sibenaller, Z, Stout, L, Walter, A, Herr, D, Vedadi, N, Bartlett, R, Thompson, S, Hoffman, J, Ying, X, Williams, B, Sanchez, E, Akwani, C, Kennedy, R, Elhadi, M, Griffee, M, Mone, M, Ciullo, A, Kida, Y, Roca, R, Riera, J, Contreras, S, Alegre, C, Kay, C, Fischer, I, Renner, E, Taniguci, H, Lee, J, Plotkin, D, Citarella, B, Merson, L, Hartley, E, Lubis, B, Ikeyama, T, Alhamad, A, Fathi, M, Hadhoud, M, Alhouri, H, Mechi, A, Alyasiri, M, Elsaid, M, Shahla, H, Bhaskar, B, Jung, J, Mcguinness, S, Eastwood, G, Marta, S, Guarracino, F, Gerle, S, Coxon, E, Claro, B, Eleisawy, M, Osama, H, Loverde, D, Patil, N, Parrini, V, Mcbride, A, Negaard, K, Ratsch, A, Uribe, J, Peris, A, Sanders, M, Emerson, D, Kamal, M, Faida, H, Povoa, P, Francis, R, Cherif, A, Joseph, S, Di Nardo, M, Heard, M, Kyle, K, Blackwell, R, Ouyahia, A, Biston, P, Jeong, H, Smith, R, Prawira, Y, Garcia, A, Salterain, N, Meyns, B, Elnasser, M, Moreno, M, Walia, R, Mehta, A, Schweda, A, Williams, M, Emadamkhatirah, Kim, K, Assad, A, Giraldo, E, Karolak, W, Balik, M, Pocock, E, Gajkowski, E, Masafumi, K, Barrett, N, Takeyama, Y, Park, S, Amin, F, Andriyani, F, Sudakevych, S, Schnur, J, Vera, M, Cornejo, R, Schwarz, P, Mardini, A, de Paula, T, Neto, A, Villoldo, A, Colafranceschi, A, Iglesias, A, Granjean, J, Melro, L, Romualdo, G, Gaia, D, Souza, H, Galas, F, Mendiluce, R, Sosa, A, Martinez, I, Kurosawa, H, Almoshantaf, M, Salgado, J, Hugi-Mayr, B, Charbonneau, E, Barzilai, V, Monteiro, V, de Souza, R, Harper, M, Siddig, N, Suzuki, H, Adams, C, Brieva, J, Khamees, A, Graige, F, Supriatna, M, Nyale, G, Eltatar, F, Fatani, J, Baeissa, H, Masri, A, Rabie, A, Hui, M, Yamane, M, Jung, H, Margaret, A, Nacpil, N, Ruck, K, Bakken, R, Jara, C, Felton, T, Tharwat, S, Berra, L, Shah, B, Chakraborty, A, Cardona, M, Capatos, G, Akkanti, B, Orija, A, Jain, H, Ito, A, Muftah, M, Housni, B, Aldhalia, A, Low, S, Iihara, K, Chavez, J, Ramanathan, K, Naidoo, K, Seppelt, I, Vandyk, M, Macdonald, S, Hafez, W, Mcgregor, R, Siebenaler, T, Flynn, H, Lofton, K, Aokage, T, Kvirkvelia, B, Shigemitsu, K, Moscatelli, A, Fiorentino, G, Baumgaertel, M, Mba, S, Assy, J, Hutahaean, A, Roush, H, Sichting, K, Alessandri, F, Burns, D, Alkhubouli, T, Nasrallah, A, Salt, G, Garabedian, C, Millar, J, Sim, M, Mattke, A, Mcauley, D, Tadili, J, Frenzel, T, Bar-Lavie, Y, Ortiz, A, Stone, J, Attokaran, A, Farquharson, M, Patel, B, Gunning, D, Baillie, K, Adem, S, Watson, P, Tamai, K, Sajinadiyasa, G, Kanyawati, D, Salgado, M, Sassine, A, Yudo, B, Mccaul, S, Lee, B, Afek, A, Iwashita, Y, Fadlalmola, H, Semedi, B, Mansour, N, Metiva, J, Van Belle, N, Martin-Loeches, I, Al-Sadawi, M, Kirakli, C, Shimaa, A, Abdurraouf, A, Ivatt, L, Moharam, S, Woon, C, Kang, H, Smith, T, James, E, Al-Rawas, N, Almjersah, A, Iwasaki, Y, Ashour, H, Embarek, H, King-Chung, K, Gudzenko, V, Taccone, F, Perdhana, F, Lamarche, Y, Ribeiro, J, Bradic, N, Van den Bossche, K, Lansink, O, Singh, G, Debeuckelaere, G, Stelfox, H, Yi, C, Elia, J, Tribble, T, Shankar, S, Padmanabhan, R, Hallinan, B, Paoletti, L, Leyva, Y, Fykuda, T, Badulak, J, Koch, J, Janowaik, L, Hackman, A, Hernandez, D, Osofsky, J, Donadello, K, Lawang, A, Fine, J, Davidson, B, Abdehaleem, I, McNicholas B. A., Rezoagli E., Simpkin A. J., Khanna S., Suen J. Y., Yeung P., Brodie D., Bassi G. L., Pham T., Bellani G., Fraser J. F., Laffey J., Al-Dabbous T., Alfoudri H., Shamsah M., Alhadad Q., Hanan M., Elapavaluru S., Berg A., Horn C., Abdelhalim A. R. M. E., Amer A. E., Elnaggar C. O. R., Hassan A. A., Abdelaziz A., Abdelhalim M., Orabi Y. S. S. A., Alaraji Z. A., Muhaisen M. R., Almasri L., Mustafa D., Hamdan S., Al-Saba'a Y., Dalloul Z., Alkahlout M., Jaber H., Aldabbourosama O., Hussein A. A. R. M., Emad Z. K., Khaled S., Mohamed N., Hassanin E., Hamdi A., Ragab A., Azizeldin M. G., Mayasi Y., Schroll S., Meyer D., Velazco J., Ploskanych L., Fikes W., Bagewadi R., Dao M., White H., Laviena A. B., Ehlers A., Shalabi-McGuire M., Witt T., Grazioli L., Lorini L., Grandin E. W., Nunez J., Reyes T., O'Briain D., Hunter S., Ramanan M., Affleck J., Veerendra H. H., Rai S., Russell-Brown J., Nourse M., Joseph M., Mitchell B., Tenzer M., Abe R., Cho H. J., Jeong I. S., Rahman N., Kakar V., Sun H., Hanley A., Brozzi N., Mehkri O., Krishnan S., Duggal A., Houltham S., Graf J., Diaz R., Orrego R., Delgado C., Gonzalez J., Sanchez M. S., Piagnerelli M., Sarrazin J. V., Zabert G., Espinosa L., Delgado P., Delgado V., Rincon D. F. B., Yanten A. M. M., Duque M. B., Abouelmagd K., Elhazmi A., Al-Hudaib A., Javidfar J., Callahan M., Dong A., D'Orleans C. C., Taufik M. A., Wardoyo E. Y., Gunawan M., Trisnaningrum N. S., Irawany V., Rayhan M., Panigada M., Pesenti A., Zanella A., Grasselli G., Colombo S., Martinet C., Florio G., Antonelli M., Carelli S., Grieco D. L., Asaki M., Hoshino K., Salazar L., Monsalve M. A. M., McNicholas B., Cosgrave D., Atif M., Qutishat F., Laffey C., Van Der Walt M., McCaffrey J., Bone A., Hakeem Y., Winearls J., Tallott M., Thomson D., Joubert I., Arnold-Day C., Piercy J., van Zyl Smit R., Miller M., Seymour L., van Heyningen F., Teyangesikayi G., Fredericks D., Hssain A. A., Aliudin J., Alqahtani A. -R., Mohamed K., Mohamed A., Tan D., Villanueva J., Zaqout A., Kurtzman E., Ademi A., Dobrita A., El Aoudi K., Segura J., Giwangkancana G., Ohshimo S., Osatnik J., Joosten A., Torres A., Yang M., Motos A., Luna C., Arancibia F., Williams V., Noel A., Luque N., Fantini M., Garcia R. N. J., Alvarez E. C., Greti A., Ceccato A., Sanchez A., Vazquez A. L., Roche-Campo F., Franch-Llasat D., Tuazon D., Amato M., Cassimiro L., Pola F., Ribeiro F., Fonseca G., Dalton H., Desai M., Osborn E., Deeb H., Arcadipane A., Martucci G., Panarello G., Vitiello S., Bianco C., Occhipinti G., Rossetti M., Cuffaro R., Cho S. -M., Whitman G., El Sayed M., Mokhtar W., El-Shenawy E., Shimizu H., Moriyama N., Kim J. -B., Kitamura N., Gebauer J., Yokoyama T., Al-Fares A., Buabbas S., Alamad E., Alawadhi F., Alawadi K., Khalefa M. A., Al Ajeel N. A. A., Aly M. F., Al-Saleh A., Naanouh A., Elshourbgy A. M., Gad M. Y., ElRazaz R. M., Khadadah I., Almumin A. M., Altarakma H., Albannay H., Alsaleh M. K., Radwan M. S. A., Saadallah I. A., Tanaka H., Hashimoto S., Yamazaki M., Oh T. -H., Epler M., Forney C., Kruse L., Feister J., Williamson J., Grobengieser K., Gnall E., Golden S., Caroline M., Shapiro T., Karaj C., Thome L., Sher L., Vanderland M., Welch M., McDermott S., Brain M., Mineall S., Unwin M., Chen L., Trezise T., McKeon L., Kimura D., Brazzi L., Sales G., Montrucchio G., Ogston T., Nagpal D., Fischer K., Lorusso R., van Bussell B., De Piero M. E., Mariani S., Rangappa R., Shetty R. M., Rai P. S., Ganesan A., Esperatti M., Fuentes N. A., Gonzalez M. E., Carton E. G., Sen A., Palacios A., Rainey D., Samoukoviv G., Campisi J., Durham L., Neumann E., Seefeldt C., Falcucci O., Emmrich A., Guy J., Johns C., Potzner K., Zimmermann C., Espinal A., Buchtele N., Schwameis M., Korhnfehl A., Brock R., Staudinger T., Stecher S. -S., Barnikel M., Anton S., Pawlikowski A., Zaaqoq A., Galloway L. A., Merley C., Nichol A., Csete M., Quesada L., Saba I., Kasugai D., Hiraiwa H., Tanaka T., Marwali E., Purnama Y., Dewayanti S. R., Juzar D. A., Siagian D., Chen Y. -S., Ogino M., Nasa P., Matthew C., Majeed N. A., Ratsep I., Post A. -M., Sillaots P., Krund A., Lehiste M. -H., Lepik T., Manetta F., Mihelis E., Sarmiento I. C., Narasimhan M., Varrone M., Komats M., Garcia-Diaz J., Harmon C., Satyapriya S. V., Bhatt A., Mokadam N. A., Uribe A., Gonzalez A., Shi H., McKeown J., Pasek J., Fiorda J., Echeverria M., Moreno R., Zakhary B., Cavana M., Cucino A., Foti G., Giani M., Fumagalli B., Chiumello D., Castagna V., Dell'Amore A., Navalesi P., Shum H. -P., Vuysteke A., Usman A., Acker A., Smood B., Mergler B., Sertic F., Subramanian M., Sperry A., Rizer N., Burhan E., Rasmin M., Akmal E., Sitompul F., Lolong N., Naivedh B., Erickson S., Barrett P., Dean D., Daugherty J., Loforte A., Khan I., Quraishi M. A., DeSantis O., So D., Kandamby D., Mandei J. M., Natanael H., YudhaLantang E., Lantang A., Wijaya S. O., Jung A., Ng G., Ng W. Y., Ng P. Y., Fang S., Tabah A., Ratcliffe M., Duroux M., Alajeeli A., Tarhabat A., Adachi S., Nakao S., Blanco P., Prieto A., Sanchez J., Nicholson M., Butt W., Serratore A., Delzoppo C., Janin P., Yarad E., Totaro R., Coles J., Pujo B., Balk R., Vissing A., Kapania E., Hays J., Fox S., Yantosh G., Mishin P., Yuliarto S., Santoso K. H., Djajalaksana S., Fatoni A. Z., Fukuda M., Liu K., Pelosi P., Battaglini D., Jimenez J. F. M., Bastos D., Gaiao S., Rusmawatiningtyas D., Cho Y. -J., Lee S. H., Kawasaki T., Munshi L., Sakiyalak P., Nitayavardhana P., Elagili M. B., Salem T. A. A., Seitz T., Arora R., Kent D., Marino D., Parwar S., Cheng A., Miller J., Fujitani S., Shimizu N., Madhok J., Owyang C., Buscher H., Reynolds C., Maasikas O., AleksanBeljantsev, Mihnovits V., Akimoto T., Aizawa M., Horibe K., Onodera R., Hodgson C., Burrell A., Young M., George T., Shekar K., McGuinness N., Irvine L., Flynn B., Endo T., Sugiyama K., Shimizu K., Fan E., Exconde K., Ichiba S., Binnawara M., Lussier L., Lotz G., Malfertheiner M., Maier L., Dreier E., Kusumastuti N. P., McCloskey C., Dabaliz A. -A., Elshazly T. B., Smith J., Szuldrzynski K. S., Bielanski P., Wille K., Murthy S., Parhar K. K. S., Fiest K. M., Codan C., Shahid A., Fayed M., Evans T., Garcia R., Gutierrez A., Song T., Rose R., Bennett S., Richardson D., Peek G., Arora L., Rappapport K., Rudolph K., Sibenaller Z., Stout L., Walter A., Herr D., Vedadi N., Bartlett R., Thompson S., Hoffman J., Ying X., Williams B., Sanchez E., Akwani C., Kennedy R., Elhadi M., Griffee M., Mone M., Ciullo A., Kida Y., Roca R. F., Riera J. I., Contreras S., Alegre C., Kay C., Fischer I., Renner E., Taniguci H., Lee J., Plotkin D., Citarella B. W., Merson L., Hartley E., Lubis B., Ikeyama T., Alhamad A., Fathi M., Hadhoud M. M., Alhouri H., Mechi A., Alyasiri M. S., Elsaid M. Z. A., Shahla H., Bhaskar B., Jung J. -S., McGuinness S., Eastwood G., Marta S. R., Guarracino F., Gerle S., Coxon E., Claro B., Eleisawy M., Osama H., Loverde D., Patil N., Parrini V., McBride A., Negaard K., Ratsch A., Uribe J. D., Peris A., Sanders M., Emerson D., Kamal M., Faida H., Povoa P., Francis R., Cherif A., Joseph S., Di Nardo M., Heard M., Kyle K., Blackwell R. A., Ouyahia A., Biston P., Jeong H. W., Smith R., Prawira Y., Garcia A. H., Salterain N., Meyns B., Elnasser M., Moreno M., Walia R., Mehta A., Schweda A., Williams M., EmadAmkhatirah, Kim K. H., Assad A., Giraldo E., Karolak W., Balik M., Pocock E., Gajkowski E., Masafumi K., Barrett N., Takeyama Y., Park S., Amin F., Andriyani F. M., Sudakevych S., Schnur J., Vera M., Cornejo R., Schwarz P., Mardini A. C., de Paula T., Neto A. S., Villoldo A., Colafranceschi A. S., Iglesias A. U., Granjean J., Melro L. M. G., Romualdo G. F., Gaia D., Souza H., Galas F., Mendiluce R. M., Sosa A., Martinez I., Kurosawa H., Almoshantaf M. B., Salgado J., Hugi-Mayr B., Charbonneau E., Barzilai V. S., Monteiro V., de Souza R. R., Harper M., Siddig N., Suzuki H., Adams C., Brieva J., Khamees A., Graige F., Supriatna M., Nyale G., Eltatar F. S., Fatani J., Baeissa H., Masri A. A. L., Rabie A., Hui M. Y., Yamane M., Jung H., Margaret A. M., Nacpil N., Ruck K., Bakken R., Jara C., Felton T., Tharwat S., Berra L., Shah B., Chakraborty A., Cardona M., Capatos G., Akkanti B., Orija A., Jain H., Ito A., Muftah M., Housni B., Aldhalia A., Low S., Iihara K., Chavez J., Ramanathan K., Naidoo K., Seppelt I., VanDyk M., MacDonald S., Hafez W., McGregor R., Siebenaler T., Flynn H., Lofton K., Aokage T., Kvirkvelia B., Shigemitsu K., Moscatelli A., Fiorentino G., Baumgaertel M., Mba S. E., Assy J., Hutahaean A., Roush H., Sichting K. A., Alessandri F., Burns D., Alkhubouli T. H., Nasrallah A., Salt G., Garabedian C. P., Millar J., Sim M., Mattke A., McAuley D., Tadili J., Frenzel T., Bar-Lavie Y., Ortiz A. B., Stone J., Attokaran A., Farquharson M., Patel B., Gunning D., Baillie K., Adem S., Watson P., Tamai K., Sajinadiyasa G. K., Kanyawati D., Salgado M., Sassine A., Yudo B., McCaul S., Lee B., Lee S. M., Afek A., Iwashita Y., Fadlalmola H., Semedi B. P., Mansour N. M., Metiva J., Van Belle N., Martin-Loeches I., Al-Sadawi M., Kirakli C., Shimaa A. -T., Abdurraouf A., Ivatt L., Moharam S., Woon C. Y., Kang H. M., Smith T., James E., Al-Rawas N., Almjersah A., Iwasaki Y., Ashour H., Embarek H., King-Chung K. C., Gudzenko V., Taccone F., Perdhana F., Lamarche Y., Ribeiro J. M., Bradic N., Van den Bossche K., Lansink O., Singh G., Debeuckelaere G., Stelfox H. T., Yi C., Elia J., Tribble T., Shankar S., Padmanabhan R., Hallinan B., Paoletti L., Leyva Y., Fykuda T., Badulak J., Koch J., Janowaik L., Hackman A., Hernandez D., Osofsky J., Donadello K., Lawang A., Fine J., Davidson B., Vazquez A. O. R., Abdehaleem I., McNicholas B. A., Mcnicholas, B, Rezoagli, E, Simpkin, A, Khanna, S, Suen, J, Yeung, P, Brodie, D, Bassi, G, Pham, T, Bellani, G, Fraser, J, Laffey, J, Al-Dabbous, T, Alfoudri, H, Shamsah, M, Alhadad, Q, Hanan, M, Elapavaluru, S, Berg, A, Horn, C, Abdelhalim, A, Amer, A, Elnaggar, C, Hassan, A, Abdelaziz, A, Abdelhalim, M, Orabi, Y, Alaraji, Z, Muhaisen, M, Almasri, L, Mustafa, D, Hamdan, S, Al-Saba'a, Y, Dalloul, Z, Alkahlout, M, Jaber, H, Aldabbourosama, O, Hussein, A, Emad, Z, Khaled, S, Mohamed, N, Hassanin, E, Hamdi, A, Ragab, A, Azizeldin, M, Mayasi, Y, Schroll, S, Meyer, D, Velazco, J, Ploskanych, L, Fikes, W, Bagewadi, R, Dao, M, White, H, Laviena, A, Ehlers, A, Shalabi-McGuire, M, Witt, T, Grazioli, L, Lorini, L, Grandin, E, Nunez, J, Reyes, T, O'Briain, D, Hunter, S, Ramanan, M, Affleck, J, Veerendra, H, Rai, S, Russell-Brown, J, Nourse, M, Joseph, M, Mitchell, B, Tenzer, M, Abe, R, Cho, H, Jeong, I, Rahman, N, Kakar, V, Sun, H, Hanley, A, Brozzi, N, Mehkri, O, Krishnan, S, Duggal, A, Houltham, S, Graf, J, Diaz, R, Orrego, R, Delgado, C, Gonzalez, J, Sanchez, M, Piagnerelli, M, Sarrazin, J, Zabert, G, Espinosa, L, Delgado, P, Delgado, V, Rincon, D, Yanten, A, Duque, M, Abouelmagd, K, Elhazmi, A, Al-Hudaib, A, Javidfar, J, Callahan, M, Dong, A, D'Orleans, C, Taufik, M, Wardoyo, E, Gunawan, M, Trisnaningrum, N, Irawany, V, Rayhan, M, Panigada, M, Pesenti, A, Zanella, A, Grasselli, G, Colombo, S, Martinet, C, Florio, G, Antonelli, M, Carelli, S, Grieco, D, Asaki, M, Hoshino, K, Salazar, L, Monsalve, M, Cosgrave, D, Atif, M, Qutishat, F, Laffey, C, Van Der Walt, M, Mccaffrey, J, Bone, A, Hakeem, Y, Winearls, J, Tallott, M, Thomson, D, Joubert, I, Arnold-Day, C, Piercy, J, van Zyl Smit, R, Miller, M, Seymour, L, van Heyningen, F, Teyangesikayi, G, Fredericks, D, Hssain, A, Aliudin, J, Alqahtani, A, Mohamed, K, Mohamed, A, Tan, D, Villanueva, J, Zaqout, A, Kurtzman, E, Ademi, A, Dobrita, A, El Aoudi, K, Segura, J, Giwangkancana, G, Ohshimo, S, Osatnik, J, Joosten, A, Torres, A, Yang, M, Motos, A, Luna, C, Arancibia, F, Williams, V, Noel, A, Luque, N, Fantini, M, Garcia, R, Alvarez, E, Greti, A, Ceccato, A, Sanchez, A, Vazquez, A, Roche-Campo, F, Franch-Llasat, D, Tuazon, D, Amato, M, Cassimiro, L, Pola, F, Ribeiro, F, Fonseca, G, Dalton, H, Desai, M, Osborn, E, Deeb, H, Arcadipane, A, Martucci, G, Panarello, G, Vitiello, S, Bianco, C, Occhipinti, G, Rossetti, M, Cuffaro, R, Cho, S, Whitman, G, El Sayed, M, Mokhtar, W, El-Shenawy, E, Shimizu, H, Moriyama, N, Kim, J, Kitamura, N, Gebauer, J, Yokoyama, T, Al-Fares, A, Buabbas, S, Alamad, E, Alawadhi, F, Alawadi, K, Khalefa, M, Al Ajeel, N, Aly, M, Al-Saleh, A, Naanouh, A, Elshourbgy, A, Gad, M, Elrazaz, R, Khadadah, I, Almumin, A, Altarakma, H, Albannay, H, Alsaleh, M, Radwan, M, Saadallah, I, Tanaka, H, Hashimoto, S, Yamazaki, M, Oh, T, Epler, M, Forney, C, Kruse, L, Feister, J, Williamson, J, Grobengieser, K, Gnall, E, Golden, S, Caroline, M, Shapiro, T, Karaj, C, Thome, L, Sher, L, Vanderland, M, Welch, M, Mcdermott, S, Brain, M, Mineall, S, Unwin, M, Chen, L, Trezise, T, Mckeon, L, Kimura, D, Brazzi, L, Sales, G, Montrucchio, G, Ogston, T, Nagpal, D, Fischer, K, Lorusso, R, van Bussell, B, De Piero, M, Mariani, S, Rangappa, R, Shetty, R, Rai, P, Ganesan, A, Esperatti, M, Fuentes, N, Gonzalez, M, Carton, E, Sen, A, Palacios, A, Rainey, D, Samoukoviv, G, Campisi, J, Durham, L, Neumann, E, Seefeldt, C, Falcucci, O, Emmrich, A, Guy, J, Johns, C, Potzner, K, Zimmermann, C, Espinal, A, Buchtele, N, Schwameis, M, Korhnfehl, A, Brock, R, Staudinger, T, Stecher, S, Barnikel, M, Anton, S, Pawlikowski, A, Zaaqoq, A, Galloway, L, Merley, C, Nichol, A, Csete, M, Quesada, L, Saba, I, Kasugai, D, Hiraiwa, H, Tanaka, T, Marwali, E, Purnama, Y, Dewayanti, S, Ardiyan, Juzar, D, Siagian, D, Chen, Y, Ogino, M, Nasa, P, Matthew, C, Majeed, N, Ratsep, I, Post, A, Sillaots, P, Krund, A, Lehiste, M, Lepik, T, Manetta, F, Mihelis, E, Sarmiento, I, Narasimhan, M, Varrone, M, Komats, M, Garcia-Diaz, J, Harmon, C, Satyapriya, S, Bhatt, A, Mokadam, N, Uribe, A, Gonzalez, A, Shi, H, Mckeown, J, Pasek, J, Fiorda, J, Echeverria, M, Moreno, R, Zakhary, B, Cavana, M, Cucino, A, Foti, G, Giani, M, Fumagalli, B, Chiumello, D, Castagna, V, Dell'Amore, A, Navalesi, P, Shum, H, Vuysteke, A, Usman, A, Acker, A, Smood, B, Mergler, B, Sertic, F, Subramanian, M, Sperry, A, Rizer, N, Burhan, E, Rasmin, M, Akmal, E, Sitompul, F, Lolong, N, Naivedh, B, Erickson, S, Barrett, P, Dean, D, Daugherty, J, Loforte, A, Khan, I, Quraishi, M, Desantis, O, So, D, Kandamby, D, Mandei, J, Natanael, H, Yudhalantang, E, Lantang, A, Wijaya, S, Jung, A, Ng, G, Ng, W, Ng, P, Fang, S, Tabah, A, Ratcliffe, M, Duroux, M, Alajeeli, A, Tarhabat, A, Adachi, S, Nakao, S, Blanco, P, Prieto, A, Sanchez, J, Nicholson, M, Butt, W, Serratore, A, Delzoppo, C, Janin, P, Yarad, E, Totaro, R, Coles, J, Pujo, B, Balk, R, Vissing, A, Kapania, E, Hays, J, Fox, S, Yantosh, G, Mishin, P, Yuliarto, S, Santoso, K, Djajalaksana, S, Fatoni, A, Fukuda, M, Liu, K, Pelosi, P, Battaglini, D, Jimenez, J, Bastos, D, Gaiao, S, Rusmawatiningtyas, D, Cho, Y, Lee, S, Kawasaki, T, Munshi, L, Sakiyalak, P, Nitayavardhana, P, Elagili, M, Salem, T, Seitz, T, Arora, R, Kent, D, Marino, D, Parwar, S, Cheng, A, Miller, J, Fujitani, S, Shimizu, N, Madhok, J, Owyang, C, Buscher, H, Reynolds, C, Maasikas, O, Aleksanbeljantsev, Mihnovits, V, Akimoto, T, Aizawa, M, Horibe, K, Onodera, R, Hodgson, C, Burrell, A, Young, M, George, T, Shekar, K, Mcguinness, N, Irvine, L, Flynn, B, Endo, T, Sugiyama, K, Shimizu, K, Fan, E, Exconde, K, Ichiba, S, Binnawara, M, Lussier, L, Lotz, G, Malfertheiner, M, Maier, L, Dreier, E, Kusumastuti, N, Mccloskey, C, Dabaliz, A, Elshazly, T, Smith, J, Szuldrzynski, K, Bielanski, P, Wille, K, Murthy, S, Parhar, K, Fiest, K, Codan, C, Shahid, A, Fayed, M, Evans, T, Gutierrez, A, Song, T, Rose, R, Bennett, S, Richardson, D, Peek, G, Arora, L, Rappapport, K, Rudolph, K, Sibenaller, Z, Stout, L, Walter, A, Herr, D, Vedadi, N, Bartlett, R, Thompson, S, Hoffman, J, Ying, X, Williams, B, Sanchez, E, Akwani, C, Kennedy, R, Elhadi, M, Griffee, M, Mone, M, Ciullo, A, Kida, Y, Roca, R, Riera, J, Contreras, S, Alegre, C, Kay, C, Fischer, I, Renner, E, Taniguci, H, Lee, J, Plotkin, D, Citarella, B, Merson, L, Hartley, E, Lubis, B, Ikeyama, T, Alhamad, A, Fathi, M, Hadhoud, M, Alhouri, H, Mechi, A, Alyasiri, M, Elsaid, M, Shahla, H, Bhaskar, B, Jung, J, Mcguinness, S, Eastwood, G, Marta, S, Guarracino, F, Gerle, S, Coxon, E, Claro, B, Eleisawy, M, Osama, H, Loverde, D, Patil, N, Parrini, V, Mcbride, A, Negaard, K, Ratsch, A, Uribe, J, Peris, A, Sanders, M, Emerson, D, Kamal, M, Faida, H, Povoa, P, Francis, R, Cherif, A, Joseph, S, Di Nardo, M, Heard, M, Kyle, K, Blackwell, R, Ouyahia, A, Biston, P, Jeong, H, Smith, R, Prawira, Y, Garcia, A, Salterain, N, Meyns, B, Elnasser, M, Moreno, M, Walia, R, Mehta, A, Schweda, A, Williams, M, Emadamkhatirah, Kim, K, Assad, A, Giraldo, E, Karolak, W, Balik, M, Pocock, E, Gajkowski, E, Masafumi, K, Barrett, N, Takeyama, Y, Park, S, Amin, F, Andriyani, F, Sudakevych, S, Schnur, J, Vera, M, Cornejo, R, Schwarz, P, Mardini, A, de Paula, T, Neto, A, Villoldo, A, Colafranceschi, A, Iglesias, A, Granjean, J, Melro, L, Romualdo, G, Gaia, D, Souza, H, Galas, F, Mendiluce, R, Sosa, A, Martinez, I, Kurosawa, H, Almoshantaf, M, Salgado, J, Hugi-Mayr, B, Charbonneau, E, Barzilai, V, Monteiro, V, de Souza, R, Harper, M, Siddig, N, Suzuki, H, Adams, C, Brieva, J, Khamees, A, Graige, F, Supriatna, M, Nyale, G, Eltatar, F, Fatani, J, Baeissa, H, Masri, A, Rabie, A, Hui, M, Yamane, M, Jung, H, Margaret, A, Nacpil, N, Ruck, K, Bakken, R, Jara, C, Felton, T, Tharwat, S, Berra, L, Shah, B, Chakraborty, A, Cardona, M, Capatos, G, Akkanti, B, Orija, A, Jain, H, Ito, A, Muftah, M, Housni, B, Aldhalia, A, Low, S, Iihara, K, Chavez, J, Ramanathan, K, Naidoo, K, Seppelt, I, Vandyk, M, Macdonald, S, Hafez, W, Mcgregor, R, Siebenaler, T, Flynn, H, Lofton, K, Aokage, T, Kvirkvelia, B, Shigemitsu, K, Moscatelli, A, Fiorentino, G, Baumgaertel, M, Mba, S, Assy, J, Hutahaean, A, Roush, H, Sichting, K, Alessandri, F, Burns, D, Alkhubouli, T, Nasrallah, A, Salt, G, Garabedian, C, Millar, J, Sim, M, Mattke, A, Mcauley, D, Tadili, J, Frenzel, T, Bar-Lavie, Y, Ortiz, A, Stone, J, Attokaran, A, Farquharson, M, Patel, B, Gunning, D, Baillie, K, Adem, S, Watson, P, Tamai, K, Sajinadiyasa, G, Kanyawati, D, Salgado, M, Sassine, A, Yudo, B, Mccaul, S, Lee, B, Afek, A, Iwashita, Y, Fadlalmola, H, Semedi, B, Mansour, N, Metiva, J, Van Belle, N, Martin-Loeches, I, Al-Sadawi, M, Kirakli, C, Shimaa, A, Abdurraouf, A, Ivatt, L, Moharam, S, Woon, C, Kang, H, Smith, T, James, E, Al-Rawas, N, Almjersah, A, Iwasaki, Y, Ashour, H, Embarek, H, King-Chung, K, Gudzenko, V, Taccone, F, Perdhana, F, Lamarche, Y, Ribeiro, J, Bradic, N, Van den Bossche, K, Lansink, O, Singh, G, Debeuckelaere, G, Stelfox, H, Yi, C, Elia, J, Tribble, T, Shankar, S, Padmanabhan, R, Hallinan, B, Paoletti, L, Leyva, Y, Fykuda, T, Badulak, J, Koch, J, Janowaik, L, Hackman, A, Hernandez, D, Osofsky, J, Donadello, K, Lawang, A, Fine, J, Davidson, B, Abdehaleem, I, McNicholas B. A., Rezoagli E., Simpkin A. J., Khanna S., Suen J. Y., Yeung P., Brodie D., Bassi G. L., Pham T., Bellani G., Fraser J. F., Laffey J., Al-Dabbous T., Alfoudri H., Shamsah M., Alhadad Q., Hanan M., Elapavaluru S., Berg A., Horn C., Abdelhalim A. R. M. E., Amer A. E., Elnaggar C. O. R., Hassan A. A., Abdelaziz A., Abdelhalim M., Orabi Y. S. S. A., Alaraji Z. A., Muhaisen M. R., Almasri L., Mustafa D., Hamdan S., Al-Saba'a Y., Dalloul Z., Alkahlout M., Jaber H., Aldabbourosama O., Hussein A. A. R. M., Emad Z. K., Khaled S., Mohamed N., Hassanin E., Hamdi A., Ragab A., Azizeldin M. G., Mayasi Y., Schroll S., Meyer D., Velazco J., Ploskanych L., Fikes W., Bagewadi R., Dao M., White H., Laviena A. B., Ehlers A., Shalabi-McGuire M., Witt T., Grazioli L., Lorini L., Grandin E. W., Nunez J., Reyes T., O'Briain D., Hunter S., Ramanan M., Affleck J., Veerendra H. H., Rai S., Russell-Brown J., Nourse M., Joseph M., Mitchell B., Tenzer M., Abe R., Cho H. J., Jeong I. S., Rahman N., Kakar V., Sun H., Hanley A., Brozzi N., Mehkri O., Krishnan S., Duggal A., Houltham S., Graf J., Diaz R., Orrego R., Delgado C., Gonzalez J., Sanchez M. S., Piagnerelli M., Sarrazin J. V., Zabert G., Espinosa L., Delgado P., Delgado V., Rincon D. F. B., Yanten A. M. M., Duque M. B., Abouelmagd K., Elhazmi A., Al-Hudaib A., Javidfar J., Callahan M., Dong A., D'Orleans C. C., Taufik M. A., Wardoyo E. Y., Gunawan M., Trisnaningrum N. S., Irawany V., Rayhan M., Panigada M., Pesenti A., Zanella A., Grasselli G., Colombo S., Martinet C., Florio G., Antonelli M., Carelli S., Grieco D. L., Asaki M., Hoshino K., Salazar L., Monsalve M. A. M., McNicholas B., Cosgrave D., Atif M., Qutishat F., Laffey C., Van Der Walt M., McCaffrey J., Bone A., Hakeem Y., Winearls J., Tallott M., Thomson D., Joubert I., Arnold-Day C., Piercy J., van Zyl Smit R., Miller M., Seymour L., van Heyningen F., Teyangesikayi G., Fredericks D., Hssain A. A., Aliudin J., Alqahtani A. -R., Mohamed K., Mohamed A., Tan D., Villanueva J., Zaqout A., Kurtzman E., Ademi A., Dobrita A., El Aoudi K., Segura J., Giwangkancana G., Ohshimo S., Osatnik J., Joosten A., Torres A., Yang M., Motos A., Luna C., Arancibia F., Williams V., Noel A., Luque N., Fantini M., Garcia R. N. J., Alvarez E. C., Greti A., Ceccato A., Sanchez A., Vazquez A. L., Roche-Campo F., Franch-Llasat D., Tuazon D., Amato M., Cassimiro L., Pola F., Ribeiro F., Fonseca G., Dalton H., Desai M., Osborn E., Deeb H., Arcadipane A., Martucci G., Panarello G., Vitiello S., Bianco C., Occhipinti G., Rossetti M., Cuffaro R., Cho S. -M., Whitman G., El Sayed M., Mokhtar W., El-Shenawy E., Shimizu H., Moriyama N., Kim J. -B., Kitamura N., Gebauer J., Yokoyama T., Al-Fares A., Buabbas S., Alamad E., Alawadhi F., Alawadi K., Khalefa M. A., Al Ajeel N. A. A., Aly M. F., Al-Saleh A., Naanouh A., Elshourbgy A. M., Gad M. Y., ElRazaz R. M., Khadadah I., Almumin A. M., Altarakma H., Albannay H., Alsaleh M. K., Radwan M. S. A., Saadallah I. A., Tanaka H., Hashimoto S., Yamazaki M., Oh T. -H., Epler M., Forney C., Kruse L., Feister J., Williamson J., Grobengieser K., Gnall E., Golden S., Caroline M., Shapiro T., Karaj C., Thome L., Sher L., Vanderland M., Welch M., McDermott S., Brain M., Mineall S., Unwin M., Chen L., Trezise T., McKeon L., Kimura D., Brazzi L., Sales G., Montrucchio G., Ogston T., Nagpal D., Fischer K., Lorusso R., van Bussell B., De Piero M. E., Mariani S., Rangappa R., Shetty R. M., Rai P. S., Ganesan A., Esperatti M., Fuentes N. A., Gonzalez M. E., Carton E. G., Sen A., Palacios A., Rainey D., Samoukoviv G., Campisi J., Durham L., Neumann E., Seefeldt C., Falcucci O., Emmrich A., Guy J., Johns C., Potzner K., Zimmermann C., Espinal A., Buchtele N., Schwameis M., Korhnfehl A., Brock R., Staudinger T., Stecher S. -S., Barnikel M., Anton S., Pawlikowski A., Zaaqoq A., Galloway L. A., Merley C., Nichol A., Csete M., Quesada L., Saba I., Kasugai D., Hiraiwa H., Tanaka T., Marwali E., Purnama Y., Dewayanti S. R., Juzar D. A., Siagian D., Chen Y. -S., Ogino M., Nasa P., Matthew C., Majeed N. A., Ratsep I., Post A. -M., Sillaots P., Krund A., Lehiste M. -H., Lepik T., Manetta F., Mihelis E., Sarmiento I. C., Narasimhan M., Varrone M., Komats M., Garcia-Diaz J., Harmon C., Satyapriya S. V., Bhatt A., Mokadam N. A., Uribe A., Gonzalez A., Shi H., McKeown J., Pasek J., Fiorda J., Echeverria M., Moreno R., Zakhary B., Cavana M., Cucino A., Foti G., Giani M., Fumagalli B., Chiumello D., Castagna V., Dell'Amore A., Navalesi P., Shum H. -P., Vuysteke A., Usman A., Acker A., Smood B., Mergler B., Sertic F., Subramanian M., Sperry A., Rizer N., Burhan E., Rasmin M., Akmal E., Sitompul F., Lolong N., Naivedh B., Erickson S., Barrett P., Dean D., Daugherty J., Loforte A., Khan I., Quraishi M. A., DeSantis O., So D., Kandamby D., Mandei J. M., Natanael H., YudhaLantang E., Lantang A., Wijaya S. O., Jung A., Ng G., Ng W. Y., Ng P. Y., Fang S., Tabah A., Ratcliffe M., Duroux M., Alajeeli A., Tarhabat A., Adachi S., Nakao S., Blanco P., Prieto A., Sanchez J., Nicholson M., Butt W., Serratore A., Delzoppo C., Janin P., Yarad E., Totaro R., Coles J., Pujo B., Balk R., Vissing A., Kapania E., Hays J., Fox S., Yantosh G., Mishin P., Yuliarto S., Santoso K. H., Djajalaksana S., Fatoni A. Z., Fukuda M., Liu K., Pelosi P., Battaglini D., Jimenez J. F. M., Bastos D., Gaiao S., Rusmawatiningtyas D., Cho Y. -J., Lee S. H., Kawasaki T., Munshi L., Sakiyalak P., Nitayavardhana P., Elagili M. B., Salem T. A. A., Seitz T., Arora R., Kent D., Marino D., Parwar S., Cheng A., Miller J., Fujitani S., Shimizu N., Madhok J., Owyang C., Buscher H., Reynolds C., Maasikas O., AleksanBeljantsev, Mihnovits V., Akimoto T., Aizawa M., Horibe K., Onodera R., Hodgson C., Burrell A., Young M., George T., Shekar K., McGuinness N., Irvine L., Flynn B., Endo T., Sugiyama K., Shimizu K., Fan E., Exconde K., Ichiba S., Binnawara M., Lussier L., Lotz G., Malfertheiner M., Maier L., Dreier E., Kusumastuti N. P., McCloskey C., Dabaliz A. -A., Elshazly T. B., Smith J., Szuldrzynski K. S., Bielanski P., Wille K., Murthy S., Parhar K. K. S., Fiest K. M., Codan C., Shahid A., Fayed M., Evans T., Garcia R., Gutierrez A., Song T., Rose R., Bennett S., Richardson D., Peek G., Arora L., Rappapport K., Rudolph K., Sibenaller Z., Stout L., Walter A., Herr D., Vedadi N., Bartlett R., Thompson S., Hoffman J., Ying X., Williams B., Sanchez E., Akwani C., Kennedy R., Elhadi M., Griffee M., Mone M., Ciullo A., Kida Y., Roca R. F., Riera J. I., Contreras S., Alegre C., Kay C., Fischer I., Renner E., Taniguci H., Lee J., Plotkin D., Citarella B. W., Merson L., Hartley E., Lubis B., Ikeyama T., Alhamad A., Fathi M., Hadhoud M. M., Alhouri H., Mechi A., Alyasiri M. S., Elsaid M. Z. A., Shahla H., Bhaskar B., Jung J. -S., McGuinness S., Eastwood G., Marta S. R., Guarracino F., Gerle S., Coxon E., Claro B., Eleisawy M., Osama H., Loverde D., Patil N., Parrini V., McBride A., Negaard K., Ratsch A., Uribe J. D., Peris A., Sanders M., Emerson D., Kamal M., Faida H., Povoa P., Francis R., Cherif A., Joseph S., Di Nardo M., Heard M., Kyle K., Blackwell R. A., Ouyahia A., Biston P., Jeong H. W., Smith R., Prawira Y., Garcia A. H., Salterain N., Meyns B., Elnasser M., Moreno M., Walia R., Mehta A., Schweda A., Williams M., EmadAmkhatirah, Kim K. H., Assad A., Giraldo E., Karolak W., Balik M., Pocock E., Gajkowski E., Masafumi K., Barrett N., Takeyama Y., Park S., Amin F., Andriyani F. M., Sudakevych S., Schnur J., Vera M., Cornejo R., Schwarz P., Mardini A. C., de Paula T., Neto A. S., Villoldo A., Colafranceschi A. S., Iglesias A. U., Granjean J., Melro L. M. G., Romualdo G. F., Gaia D., Souza H., Galas F., Mendiluce R. M., Sosa A., Martinez I., Kurosawa H., Almoshantaf M. B., Salgado J., Hugi-Mayr B., Charbonneau E., Barzilai V. S., Monteiro V., de Souza R. R., Harper M., Siddig N., Suzuki H., Adams C., Brieva J., Khamees A., Graige F., Supriatna M., Nyale G., Eltatar F. S., Fatani J., Baeissa H., Masri A. A. L., Rabie A., Hui M. Y., Yamane M., Jung H., Margaret A. M., Nacpil N., Ruck K., Bakken R., Jara C., Felton T., Tharwat S., Berra L., Shah B., Chakraborty A., Cardona M., Capatos G., Akkanti B., Orija A., Jain H., Ito A., Muftah M., Housni B., Aldhalia A., Low S., Iihara K., Chavez J., Ramanathan K., Naidoo K., Seppelt I., VanDyk M., MacDonald S., Hafez W., McGregor R., Siebenaler T., Flynn H., Lofton K., Aokage T., Kvirkvelia B., Shigemitsu K., Moscatelli A., Fiorentino G., Baumgaertel M., Mba S. E., Assy J., Hutahaean A., Roush H., Sichting K. A., Alessandri F., Burns D., Alkhubouli T. H., Nasrallah A., Salt G., Garabedian C. P., Millar J., Sim M., Mattke A., McAuley D., Tadili J., Frenzel T., Bar-Lavie Y., Ortiz A. B., Stone J., Attokaran A., Farquharson M., Patel B., Gunning D., Baillie K., Adem S., Watson P., Tamai K., Sajinadiyasa G. K., Kanyawati D., Salgado M., Sassine A., Yudo B., McCaul S., Lee B., Lee S. M., Afek A., Iwashita Y., Fadlalmola H., Semedi B. P., Mansour N. M., Metiva J., Van Belle N., Martin-Loeches I., Al-Sadawi M., Kirakli C., Shimaa A. -T., Abdurraouf A., Ivatt L., Moharam S., Woon C. Y., Kang H. M., Smith T., James E., Al-Rawas N., Almjersah A., Iwasaki Y., Ashour H., Embarek H., King-Chung K. C., Gudzenko V., Taccone F., Perdhana F., Lamarche Y., Ribeiro J. M., Bradic N., Van den Bossche K., Lansink O., Singh G., Debeuckelaere G., Stelfox H. T., Yi C., Elia J., Tribble T., Shankar S., Padmanabhan R., Hallinan B., Paoletti L., Leyva Y., Fykuda T., Badulak J., Koch J., Janowaik L., Hackman A., Hernandez D., Osofsky J., Donadello K., Lawang A., Fine J., Davidson B., Vazquez A. O. R., and Abdehaleem I.

Abstract

Following publication of the original article [1], the authors identified that the collaborating authors part of the collaborating author group CCCC Consortium was missing. The collaborating author group is available and included as Additional file 1 in this article.

Published
2023

3. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

Author

Li Bassi, G., Gibbons, K., Suen, J. Y., Dalton, H. J., White, N., Corley, A., Shrapnel, S., Hinton, S., Forsyth, S., Laffey, J. G., Fan, E., Fanning, J. P., Panigada, M., Bartlett, R., Brodie, D., Burrell, A., Chiumello, D., Elhazmi, A., Esperatti, M., Grasselli, G., Hodgson, C., Ichiba, S., Luna, C., Marwali, E., Merson, L., Murthy, S., Nichol, A., Ogino, M., Pelosi, P., Torres, A., P. Y., Ng, Fraser, J. F., Al-Dabbous, T., Alfoudri, H., Shamsah, M., Elapavaluru, S., Berg, A., Horn, C., Mayasi, Y., Schroll, S., Meyer, D., Velazco, J., Ploskanych, L., Fikes, W., Bagewadi, R., Dao, M., White, H., Ehlers, A., Shalabi-McGuire, M., Witt, T., Grazioli, L., Lorini, L., Grandin, E. W., Nunez, J., Reyes, T., Obriain, D., Hunter, S., Ramanan, M., Affleck, J., Veerendra, H. H., Rai, S., Russell-Brown, J., Nourse, M., Joseph, M., Mitchell, B., Tenzer, M., Abe, R., Cho, H. J., Jeong, I. S., Rahman, N., Kakar, V., Brozzi, N., Mehkri, O., Krishnan, S., Duggal, A., Houltham, S., Graf, J., Diaz, R., Orrego, R., Delgado, C., Gonzalez, J., Sanchez, M. S., Piagnerelli, M., Sarrazin, J. V., Zabert, A. /P. G., Espinosa, L., Delgado, P., Delgado, V., Rincon, D. F. B., Yanten, A. M. M., Duque, M. B., Al-Hudaib, A., Callahan, M., Taufik, M. A., Wardoyo, E. Y., Gunawan, M., Trisnaningrum, N. S., Irawany, V., Rayhan, M., Pesenti, A., Zanella, A., Leone, M., Coppola, S., Colombo, S., Antonelli, M., Carelli, S., Grieco, D. L., Asaki, M., Hoshino, K., Salazar, L., Duarte, L., Laffey, J., Mcnicholas, B., Cosgrave, D., Mccaffrey, J., Bone, A., Hakeem, Y., Winearls, J., Tallott, M., Thomson, D., Arnold-Day, C., Cupido, J., Fanie, Z., Miller, M., Seymore, L., van Straaten, D., Hssain, A. A., Aliudin, J., Alqahtani, A. -R., Mohamed, K., Mohamed, A., Tan, D., Villanueva, J., Zaqout, A., Kurtzman, E., Ademi, A., Dobrita, A., El Aoudi, K., Segura, J., Giwangkancana, G., Ohshimo, S., Hitoshi, S., Osatnik, J., Joosten, A., Yang, M., Motos, A., Arancibia, F., Williams, V., Noel, A., Luque, N., Trung, T. H., Yacoub, S., Fantini, M., Garcia, R. N. J., Alvarez, E. C., Greti, A., Ceccato, A., Sanchez, A., Vazquez, A. L., Roche-Campo, F., Franch-Llasat, D., Tuazon, D., Amato, M., Cassimiro, L., Pola, F., Ribeiro, F., Fonseca, G., Dalton, H., Desai, M., Osborn, E., Deeb, H., Arcadipane, A., Martucci, G., Panarello, G., Vitiello, C., Bianco, C., Occhipinti, G., Rossetti, M., Cuffaro, R., Cho, S. -M., Shimizu, H., Moriyama, N., Kim, J. -B., Kitamura, N., Gebauer, J., Yokoyama, T., Al-Fares, A., Buabbas, S., Alamad, E., Alawadhi, F., Alawadi, K., Tanaka, H., Hashimoto, S., Yamazaki, M., T. -H., Oh, Epler, M., Forney, C., Kruse, L., Feister, J., Williamson, J., Grobengieser, K., Gnall, E., Golden, S., Caroline, M., Shapiro, T., Karaj, C., Thome, L., Sher, L., Vanderland, M., Welch, M., Mcdermott, S., Brain, M., Mineall, S., Kimura, D., Brazzi, L., Sales, G., Ogston, T., Nagpal, D., Fischer, K., Lorusso, R., Rangappa, R., Appu, A., Carton, E. G., Sen, A., Palacios, A., Rainey, D., Samoukoviv, G., Campisi, J., Durham, L., Neumann, E., Seefeldt, C., Falcucci, O., Emmrich, A., Guy, J., Johns, C., Potzner, K., Zimmermann, C., Espinal, A., Buchtele, N., Schwameis, M., Stecher, S. -S., Singh, D., Barnikel, M., Arenz, L., Zaaqoq, A., Galloway, L. A., Merley, C., Csete, M., Quesada, L., Saba, I., Kasugai, D., Hiraiwa, H., Tanaka, T., Purnama, Y., Dewayanti, S. R., Ardiyan, Juzar, D. A., Siagian, D., Chen, Y. -S., Ratsep, I., Oigus, G., Erikson, K., Post, A. -M., Enneveer, L., Sillaots, P., Manetta, F., Mihelis, E., Sarmiento, I. C., Narasimhan, M., Varrone, M., Komats, M., Garcia-Diaz, J., Harmon, C., Satyapriya, S. V., Bhatt, A., Mokadam, N. A., Uribe, A., Gonzalez, A., Shi, H., Mckeown, J., Pasek, J., Fiorda, J., Echeverria, M., Moreno, R., Zakhary, B., Cavana, M., Cucino, A., Foti, G., Giani, M., Russotto, V., Castagna, V., Dellamore, A., Navalesi, P., Shum, H. -P., Vuysteke, A., Usman, A., Acker, A., Smood, B., Mergler, B., Sertic, F., Subramanian, M., Sperry, A., Rizer, N., Burhan, E., Rasmin, M., Akmal, E., Sitompul, F., Lolong, N., Naivedh, B., Erickson, S., Barrett, P., Dean, D., Daugherty, J., Loforte, A., Khan, I., Abraar Quraishi, M., Desantis, O., So, D., Kandamby, D., Mandei, J. M., Natanael, H., Yudhalantang, E., Lantang, A., Wijaya, S. O., Jung, A., Ng, G., W. Y., Ng, Fang, S., Tabah, A., Ratcliffe, M., Duroux, M., Adachi, S., Nakao, S., Blanco, P., Prieto, A., Sanchez, J., Nicholson, M., Butt, W., Serratore, A., Delzoppo, C., Janin, P., Yarad, E., Totaro, R., Coles, J., Pujo, B., Balk, R., Vissing, A., Kapania, E., Hays, J., Fox, S., Yantosh, G., Mishin, P., Yuliarto, S., Hari Santoso, K., Djajalaksana, S., Fatoni, A. Z., Fukuda, M., Liu, K., Battaglini, D., Jimenez, J. F. M., Bastos, D., Gaiao, S., Rusmawatiningtyas, D., Buchner, J., Cho, Y. -J., Lee, S. H., Kawasaki, T., Munshi, L., Sakiyalak, P., Nitayavardhana, P., Seitz, T., Arora, R., Kent, D., Marino, D., Parwar, S., Cheng, A., Miller, J., Fujitani, S., Shimizu, N., Madhok, J., Owyang, C., Buscher, H., Reynolds, C., Maasikas, O., Beljantsev, A., Mihnovits, V., Akimoto, T., Aizawa, M., Horibe, K., Onodera, R., Young, M., George, T., Shekar, K., Mcguinness, N., Irvine, L., Flynn, B., Endo, T., Sugiyama, K., Shimizu, K., Exconde, K., Lussier, L., Lotz, G., Malfertheiner, M., Maier, L., Dreier, E., Kusumastuti, N. P., Mccloskey, C., Dabaliz, A. -A., Elshazly, T. B., Smith, J., Szuldrzynski, K. S., Bielanski, P., Wille, K., Parhar, K. K. S., Fiest, K. M., Codan, C., Shahid, A., Fayed, M., Evans, T., Garcia, R., Gutierrez, A., Song, T., Rose, R., Bennett, S., Richardson, D., Peek, G., Arora, L., Rappapport, K., Rudolph, K., Sibenaller, Z., Stout, L., Walter, A., Herr, D., Vedadi, N., Thompson, S., Sindt, L., Rajnic, S., Ewald, C., Hoffman, J., Ying, X., Kennedy, R., Griffee, M., Ciullo, A., Kida, Y., Roca, R. F., Riera, J. I., Contreras, S., Alegre, C., Kay, C., Fischer, I., Renner, E., Taniguci, H., Fraser, J., Bassi, G. L., Suen, J., Barnett, A., Pearse, I., Abbate, G., Hassan, H., Heinsar, S., Karnik, V. A., Ki, K., Oneill, H. F., Obonyo, N., Pimenta, L. P., Reid, J. D., Sato, K., Vuorinen, A., Wildi, K. S., Wood, E. S., Yerkovich, S., Lee, J., Plotkin, D., Citarella, B. W., Hartley, E., Lubis, B., Ikeyama, T., Bhaskar, B., Jung, J. -S., Mcguinness, S., Eastwood, G., Marta, S. R., Guarracino, F., Gerle, S., Coxon, E., Claro, B., Loverde, D., Patil, N., Parrini, V., Mcbride, A., Negaard, K., Ratsch, A., Abdelaziz, A., Uribe, J. D., Peris, A., Sanders, M., Emerson, D., Kamal, M., Povoa, P., Francis, R., Cherif, A., Joseph, S., Di Nardo, M., Heard, M., Kyle, K., Blackwell, R. A., Biston, P., Jeong, H. W., Smith, R., Prawira, Y., Montrucchio, G., Garcia, A. H., Salterain, N., Meyns, B., Moreno, M., Walia, R., Mehta, A., Schweda, A., Supriatna, M., Kirakli, C., Williams, M., Kim, K. H., Assad, A., Giraldo, E., Karolak, W., Balik, M., Pocock, E., Gajkowski, E., Masafumi, K., Barrett, N., Takeyama, Y., Park, S., Amin, F., Andriyani, F. M., Sudakevych, S., Vera, M., Cornejo, R., Schwarz, P., Mardini, A. C., de Paula, T., Neto, A. S., Villoldo, A., Colafranceschi, A. S., Iglesias, A. U., Granjean, J., Melro, L. M. G., Romualdo, G. F., Gaia, D., Souza, H., Galas, F., Mendiluce, R. M., Sosa, A., Martinez, I., Kurosawa, H., Salgado, J., Hugi-MayrCharbonneau, B. E., Barzilai, V. S., Monteiro, V., de Souza, R. R., Harper, M., Suzuki, H., Adams, C., Brieva, J., Nyale, G., Eltatar, F. S., Fatani, J., Baeissa, H., Masri, A. A., Rabie, A., Hui, M. Y., Yamane, M., Jung, H., Margaret, A. M., Nacpil, N., Ruck, K., Bakken, R., Jara, C., Felton, T., Berra, L., Shah, B., Chakraborty, A., Cardona, M., Capatos, G., Akkanti, B., Orija, A., Jain, H., Ito, A., Housni, B., Low, S., Iihara, K., Chavez, J., Ramanathan, K., Zabert, G., Naidoo, K., Seppelt, I., Vandyk, M., Macdonald, S., Mcgregor, R., Siebenaler, T., Flynn, H., Lofton, K., Aokage, T., Shigemitsu, K., Moscatelli, A., Fiorentino, G., Baumgaertel, M., Mba, S. E., Assy, J., Hutahaean, A., Roush, H., Sichting, K. A., Alessandri, F., Burns, D., Salt, G., Garabedian, C. P., Millar, J., Sim, M., Mattke, A., Mcauley, D., Tadili, J., Frenzel, T., Bar-Lavie, Y., Ortiz, A. B., Stone, J., Attokaran, A., Farquharson, M., Patel, B., Gunning, D., Baillie, K., Watson, P., Tamai, K., Sajinadiyasa, G. K., Kanyawati, D., Salgado, M., Sassine, A., Yudo, B., Mccaul, S., Lee, B., Lee, S. M., Afek, A., Iwashita, Y., Semedi, B. P., Metiva, J., Van Belle, N., Martin-Loeches, I., Ivatt, L., Woon, C. Y., Kang, H. M., Smith, T., James, E., Al-Rawas, N., Iwasaki, Y., King-Chung, K. C., Gudzenko, V., Hugi-Mayr, B., Taccone, F., Perdhana, F., Lamarche, Y., Ribeiro, J. M., Bradic, N., Van den Bossche, K., Lansink, O., Singh, G., Debeuckelaere, G., Stelfox, H. T., Yi, C., Elia, J., Tribble, T., Shankar, S., Padmanabhan, R., Hallinan, B., Paoletti, L., Leyva, Y., Fykuda, T., Badulak, J., Koch, J., Hackman, A., Janowaik, L., Hernandez, D., Osofsky, J., Donadello, K., Lawang, A., Fine, J., Davidson, B., Vazquez, A. O. R., COVID-19 Critical Care Consortium, and Consortium, COVID-19 Critical Care

Subjects
Male, Respiratory Distress Syndrome, COVID-19, Intensive care unit, Mechanical ventilation, Neuromuscular blocking agent, SARS-CoV-2, Aged, Female, Humans, Intensive Care Units, Middle Aged, Propensity Score, Respiration, Artificial, Neuromuscular Blocking Agents, Respiration, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Settore MED/41 - Anestesiologia, Critical Care and Intensive Care Medicine, COVID-19 Drug Treatment, Artificial, Human medicine
Abstract

Background The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis. Methods We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression. Results Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0–25) and 25 (IQR 7–26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0–87) and 87 (IQR 0–88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177). Conclusions In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting.

Published
2022
Full Text
View/download PDF

4. MortalitY in caRdIAc surgery (MYRIAD): A randomizeD controlled trial of volatile anesthetics. Rationale and design

Author

Landoni, G, Lomivorotov, V, Pisano, A, Nigro Neto, C, Benedetto, U, Biondi Zoccai, G, Gemma, M, Frassoni, S, Agro, F, Baiocchi, M, Barbosa Gomes Galas, F, Bautin, A, Bradic, N, Carollo, C, Crescenzi, G, Elnakera, A, El-Tahan, M, Fominskiy, E, Farag, A, Gazivoda, G, Gianni, S, Grigoryev, E, Guarracino, F, Hanafi, S, Huang, W, Kunst, G, Kunstyr, J, Lei, C, Lembo, R, Li, Z, Likhvantsev, V, Lozovskiy, A, Ma, J, Monaco, F, Navalesi, P, Nazar, B, Pasyuga, V, Porteri, E, Royse, C, Ruggeri, L, Riha, H, Santos Silva, F, Severi, L, Shmyrev, V, Uvaliev, N, Wang, C, Winterton, D, Yong, C, Yu, J, Bellomo, R, Zangrillo, A, Landoni G., Lomivorotov V., Pisano A., Nigro Neto C., Benedetto U., Biondi Zoccai G., Gemma M., Frassoni S., Agro F. E., Baiocchi M., Barbosa Gomes Galas F. R., Bautin A., Bradic N., Carollo C., Crescenzi G., Elnakera A. M., El-Tahan M. R., Fominskiy E., Farag A. G., Gazivoda G., Gianni S., Grigoryev E., Guarracino F., Hanafi S., Huang W., Kunst G., Kunstyr J., Lei C., Lembo R., Li Z. -J., Likhvantsev V., Lozovskiy A., Ma J., Monaco F., Navalesi P., Nazar B., Pasyuga V., Porteri E., Royse C., Ruggeri L., Riha H., Santos Silva F., Severi L., Shmyrev V., Uvaliev N., Wang C. B., Wang C. -Y., Winterton D., Yong C. -Y., Yu J., Bellomo R., Zangrillo A., Landoni, G, Lomivorotov, V, Pisano, A, Nigro Neto, C, Benedetto, U, Biondi Zoccai, G, Gemma, M, Frassoni, S, Agro, F, Baiocchi, M, Barbosa Gomes Galas, F, Bautin, A, Bradic, N, Carollo, C, Crescenzi, G, Elnakera, A, El-Tahan, M, Fominskiy, E, Farag, A, Gazivoda, G, Gianni, S, Grigoryev, E, Guarracino, F, Hanafi, S, Huang, W, Kunst, G, Kunstyr, J, Lei, C, Lembo, R, Li, Z, Likhvantsev, V, Lozovskiy, A, Ma, J, Monaco, F, Navalesi, P, Nazar, B, Pasyuga, V, Porteri, E, Royse, C, Ruggeri, L, Riha, H, Santos Silva, F, Severi, L, Shmyrev, V, Uvaliev, N, Wang, C, Winterton, D, Yong, C, Yu, J, Bellomo, R, Zangrillo, A, Landoni G., Lomivorotov V., Pisano A., Nigro Neto C., Benedetto U., Biondi Zoccai G., Gemma M., Frassoni S., Agro F. E., Baiocchi M., Barbosa Gomes Galas F. R., Bautin A., Bradic N., Carollo C., Crescenzi G., Elnakera A. M., El-Tahan M. R., Fominskiy E., Farag A. G., Gazivoda G., Gianni S., Grigoryev E., Guarracino F., Hanafi S., Huang W., Kunst G., Kunstyr J., Lei C., Lembo R., Li Z. -J., Likhvantsev V., Lozovskiy A., Ma J., Monaco F., Navalesi P., Nazar B., Pasyuga V., Porteri E., Royse C., Ruggeri L., Riha H., Santos Silva F., Severi L., Shmyrev V., Uvaliev N., Wang C. B., Wang C. -Y., Winterton D., Yong C. -Y., Yu J., Bellomo R., and Zangrillo A.

Abstract

Objective There is initial evidence that the use of volatile anesthetics can reduce the postoperative release of cardiac troponin I, the need for inotropic support, and the number of patients requiring prolonged hospitalization following coronary artery bypass graft (CABG) surgery. Nevertheless, small randomized controlled trials have failed to demonstrate a survival advantage. Thus, whether volatile anesthetics improve the postoperative outcome of cardiac surgical patients remains uncertain. An adequately powered randomized controlled trial appears desirable. Design Single blinded, international, multicenter randomized controlled trial with 1:1 allocation ratio. Setting Tertiary and University hospitals. Interventions Patients (n = 10,600) undergoing coronary artery bypass graft will be randomized to receive either volatile anesthetic as part of the anesthetic plan, or total intravenous anesthesia. Measurements and main results The primary end point of the study will be one-year mortality (any cause). Secondary endpoints will be 30-day mortality; 30-day death or non-fatal myocardial infarction (composite endpoint); cardiac mortality at 30 day and at one year; incidence of hospital re-admission during the one year follow-up period and duration of intensive care unit, and hospital stay. The sample size is based on the hypothesis that volatile anesthetics will reduce 1-year unadjusted mortality from 3% to 2%, using a two-sided alpha error of 0.05, and a power of 0.9. Conclusions The trial will determine whether the simple intervention of adding a volatile anesthetic, an intervention that can be implemented by all anesthesiologists, can improve one-year survival in patients undergoing coronary artery bypass graft surgery.

Published
2017

13. A Randomized Trial of Intravenous Amino Acids for Kidney Protection.

Author

Landoni, G., Monaco, F., Ti, L. K., Redaelli, M. Baiardo, Bradic, N., Comis, M., Kotani, Y., Brambillasca, C., Garofalo, E., Scandroglio, A. M., Viscido, C., Paternoster, G., Franco, A., Porta, S., Ferrod, F., Calabrò, M. G., Pisano, A., Vendramin, I., Barucco, G., and Federici, F.

Subjects
*AMINO acids, *CARDIOPULMONARY bypass, *ACUTE kidney failure, *AMINO group, *PHYSIOLOGIC salines, *CARDIAC surgery
Abstract

Background: Acute kidney injury (AKI) is a serious and common complication of cardiac surgery, for which reduced kidney perfusion is a key contributing factor. Intravenous amino acids increase kidney perfusion and recruit renal functional reserve. However, the efficacy of amino acids in reducing the occurrence of AKI after cardiac surgery is uncertain. Methods: In a multinational, double-blind trial, we randomly assigned adult patients who were scheduled to undergo cardiac surgery with cardiopulmonary bypass to receive an intravenous infusion of either a balanced mixture of amino acids, at a dose of 2 g per kilogram of ideal body weight per day, or placebo (Ringer's solution) for up to 3 days. The primary outcome was the occurrence of AKI, defined according to the Kidney Disease: Improving Global Outcomes creatinine criteria. Secondary outcomes included the severity of AKI, the use and duration of kidney-replacement therapy, and all-cause 30-day mortality. Results: We recruited 3511 patients at 22 centers in three countries and assigned 1759 patients to the amino acid group and 1752 to the placebo group. AKI occurred in 474 patients (26.9%) in the amino acid group and in 555 (31.7%) in the placebo group (relative risk, 0.85; 95% confidence interval [CI], 0.77 to 0.94; P = 0.002). Stage 3 AKI occurred in 29 patients (1.6%) and 52 patients (3.0%), respectively (relative risk, 0.56; 95% CI, 0.35 to 0.87). Kidney-replacement therapy was used in 24 patients (1.4%) in the amino acid group and in 33 patients (1.9%) in the placebo group. There were no substantial differences between the two groups in other secondary outcomes or in adverse events. Conclusions: Among adult patients undergoing cardiac surgery, infusion of amino acids reduced the occurrence of AKI. (Funded by the Italian Ministry of Health; PROTECTION ClinicalTrials.gov number, NCT03709264.). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials

Author

Bove T, Matteazzi A, Belletti A, Paternoster G, Omar Saleh, Taddeo D, Dossi R, Greco T, Bradic N, Husedzinovic I, Nigro Neto C, Vv, Lomivorotov, and Mg, Calabrò

Subjects
critical care, levosimendan, acute kidney injury, renal replacement therapy, acute kidney injury, critical care, levosimendan, renal replacement therapy
Abstract

Introduction: The incidence of Acute Kidney Injury is nowadays high in critically ill patients. Its etiology is multifactorial and a primary role is played by low cardiac output syndrome. Everything targeted to normalize cardiac output should increase the renal perfusion and abolish the secondary vasoconstriction. Levosimendan is a calcium sensitizer drug with inotropic properties that improves cardiac output and seems to increase renal blood flow. The aim of this meta-analysis was to evaluate the role of levosimendan in critically ill patients with or at risk of Acute Kidney Injury. Methods: We performed a meta-analysis of randomized controlled trials searching for trials that compared levosimendan with any comparator. The endpoints were the number of patients receiving Renal Replacement Therapy after randomization and the number of patients developing Acute Kidney Injury. Results: Final analysis included 33 trials and 3, 879 patients (2, 024 levosimendan and 1, 855 control). The overall analysis showed that the use of levosimendan was associated with a significant reduction in the risk of Renal Replacement Therapy (17 of 492 [3.5%] in the levosimendan group versus 37 of 427 [8.7%] in the control group, relative risk =0.52 [0.32 to 0.86], p for effect =0.01) and of Acute Kidney Injury (114 of 1, 598 [7.1%] in the levosimendan group versus 143 of 1, 529 [9.4%] in the control arm, relative risk =0.79 [0.63 to 0.99], p for effect =0.048). Conclusions: This meta-analysis suggests that the use of levosimendan is associated with a significant reduction of Renal Replacement Therapy in critically ill patients.

18. Effect of Volatile Anesthetics on Myocardial Infarction After Coronary Artery Surgery: A Post Hoc Analysis of a Randomized Trial

Author

Zangrillo, Alberto, Lomivorotov, Vladimir, Pasyuga, Vadim, Belletti, Alessandro, Gazivoda, Gordana, Monaco, Fabrizio, Nigro Neto, Caetano, Likhvantsev, Valery, Bradic, Nikola, Lozovskiy, Andrey, Lei, Chong, Bukamal, Nazar, Santos Silva, Fernanda, Bautin, Andrey, Ma, Jun, Yen Yong, Chow, Carollo, Cristiana, Kunstyr, Jan, Wang, Chew Yin, Grigoryev, Evgeny, Riha, Hynek, Wang, Chengbin, El-Tahan, Mohamed, Scandroglio, Anna Mara, Mansor, Marzida, Lembo, Rosalba, Ponomarev, Dmitry, Lucena Bezerra, Francisco José, Ruggeri, Laura, Chernyavskiy, Alexander, Xu, Junmei, Tarasov, Dmitry, Navalesi, Paolo, Yavorovskiy, Andrey, Bove, Tiziana, Kuzovlev, Artem, Hajjar, Ludhmila, Landoni, Giovanni, MYRIAD Study Group, Zangrillo, A., Lomivorotov, V. V., Pasyuga, V. V., Belletti, A., Gazivoda, G., Monaco, F., Nigro Neto, C., Likhvantsev, V. V., Bradic, N., Lozovskiy, A., Lei, C., Bukamal, N. A. R., Silva, F. S., Bautin, A. E., Ma, J., Yong, C. Y., Carollo, C., Kunstyr, J., Wang, C. Y., Grigoryev, E. V., Riha, H., Wang, C., El-Tahan, M. R., Scandroglio, A. M., Mansor, M., Lembo, R., Ponomarev, D. N., Bezerra, F. J. L., Ruggeri, L., Chernyavskiy, A. M., Xu, J., Tarasov, D. G., Navalesi, P., Yavorovskiy, A., Bove, T., Kuzovlev, A., Hajjar, L. A., and Landoni, G.

Subjects
cancer, cardiac surgery, cardioprotection, mortality, myocardial infarction, volatile anesthetics, Myocardial Infarction, Middle Aged, Sevoflurane, Anesthesiology and Pain Medicine, Postoperative Complications, Anesthetics, Inhalation, Humans, volatile anesthetic, Coronary Artery Bypass, Cardiology and Cardiovascular Medicine, Propofol, Anesthetics, Intravenous, Aged
Abstract

Objective: To investigate the effect of volatile anesthetics on the rates of postoperative myocardial infarction (MI) and cardiac death after coronary artery bypass graft (CABG). Design: A post hoc analysis of a randomized trial. Setting: Cardiac surgical operating rooms. Participants: Patients undergoing elective, isolated CABG. Interventions: Patients were randomized to receive a volatile anesthetic (desflurane, isoflurane, or sevoflurane) or total intravenous anesthesia (TIVA). The primary outcome was hemodynamically relevant MI (MI requiring high-dose inotropic support or prolonged intensive care unit stay) occurring within 48 hours from surgery. The secondary outcome was 1-year death due to cardiac causes. Measurements and main results: A total of 5, 400 patients were enrolled between April 2014 and September 2017 (2, 709 patients randomized to the volatile anesthetics group and 2, 691 to TIVA). The mean age was 62 ± 8.4 years, and the median baseline ejection fraction was 57% (50-67), without differences between the 2 groups. Patients in the volatile group had a lower incidence of MI with hemodynamic complications both in the per- protocol (14 of 2, 530 [0.6%] v 27 of 2, 501 [1.1%] in the TIVA group ; p = 0.038) and as- treated analyses (16 of 2, 708 [0.6%] v 29 of 2, 617 [1.1%] in the TIVA group ; p = 0.039), but not in the intention-to-treat analysis (17 of 2, 663 [0.6%] v 28 of 2, 667 [1.0%] in the TIVA group ; p = 0.10). Overall, deaths due to cardiac causes were lower in the volatile group (23 of 2, 685 [0.9%] v 40 of 2, 668 [1.5%] than in the TIVA group ; p = 0.03). Conclusions: An anesthetic regimen, including volatile agents, may be associated with a lower rate of postoperative MI with hemodynamic complication in patients undergoing CABG. Furthermore, it may reduce long- term cardiac mortality.

Published
2022

19. Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design

Author

Ingrid Marcela Pabon, Barbara Azzali, Mattia Bozzetti, Vincenzo Pota, Antonio De Sio, Andrey Yavorovskiy, Natascia D'Andrea, Rosetta Lobreglio, Andrea Della Selva, Evgeny Fominskiy, Federico Canavosio, Barbara Ferrara, Vittorio Pazzanese, Francesca Gallicchio, Nicola Pasculli, Valery Likhvantsev, Eugenio Garofalo, Sergio Colombo, Anna Mara Scandroglio, Felice Eugenio Agrò, Margherita Tozzi, Gianluca Paternoster, Francesco Corradi, Tiziana Bove, Filippo Palmesino, Elena Momesso, Luigi Vetrugno, Francesco Giuseppe Nisi, Giorgia Montrucchio, Daniela Missio, Mara Bernasconi, Giacomo Monti, Mariano Ballestra, Marco Gemma, Giovanni Marino, Silvia Ajello, Alberto Zangrillo, Rosalba Lembo, Maria Grazia Calabrò, Romina Perone, Andrea Bruni, Pavel Nogtev, Alberto Cappelletti, Gabriele Finco, Daniele Cristadoro, Leonarda Pia Cantatore, Marina Pieri, Sofia Ananiadou, Italo Calamai, Chiara Millin, A. Mattei, Luca Cabrini, Marina Petrova, Valentina Paola Plumari, Nicoletta Boffa, Davide Maraggia, Elena Moizo, Gianna Curci, Giovanni Landoni, Giuseppe Biondi-Zoccai, Giuseppe Giardina, Giacomo Iapichino, Carola Galbiati, Fabio Guarracino, Antonella Cotoia, Matteo Marzaroli, Nikola Bradic, Umberto Benedetto, Giorgio Gallioli, Fabrizio D'Ascenzo, Francesco Forfori, Fabio Toffoletto, Milena Mucci, Manuela Mainetti, Monti, G., Galbiati, C., Toffoletto, F., Calabro, M. G., Colombo, S., Ferrara, B., Giardina, G., Lembo, R., Marzaroli, M., Moizo, E., Mucci, M., Pasculli, N., Plumari, V. P., Scandroglio, A. M., Tozzi, M., Momesso, E., Boffa, N., Lobreglio, R., Montrucchio, G., Guarracino, F., Benedetto, U., Biondi-Zoccai, G., D'Ascenzo, F., D'Andrea, N., Paternoster, G., Ananiadou, S., Ballestra, M., De Sio, A., Pota, V., Cotoia, A., Della Selva, A., Bruni, A., Iapichino, G., Bradic, N., Corradi, F., Gemma, M., Nogtev, P., Petrova, M., Agro, F. E., Cabrini, L., Forfori, F., Likhvantsev, V., Bove, T., Finco, G., Landoni, G., Zangrillo, A., Ajello, S., Cappelletti, A. M., Fominskiy, E., Nisi, F. G., Pazzanese, V., Pieri, M., Canavosio, F., Palmesino, F., Bernasconi, M., Gallioli, G., Marino, G., Vetrugno, L., Millin, C., Missio, D., Gallicchio, F., Azzali, B., Bozzetti, M., Cristadoro, D., Perone, R., Cantatore, L. P., Curci, G., Pabon, I. M., Garofalo, E., Mainetti, M., Calamai, I., Maraggia, D., Mattei, A., Yavorovskiy, A., Monti, Giacomo, Galbiati, Carola, Toffoletto, Fabio, Calabrò, Maria Grazia, Colombo, Sergio, Ferrara, Barbara, Giardina, Giuseppe, Lembo, Rosalba, Marzaroli, Matteo, Moizo, Elena, Mucci, Milena, Pasculli, Nicola, Plumari, Valentina, Scandroglio, Anna Mara, Tozzi, Margherita, Momesso, Elena, Boffa, Nicoletta, Lobreglio, Rosetta, Montrucchio, Giorgia, Guarracino, Fabio, Benedetto, Umberto, Biondi-Zoccai, Giuseppe, D'Ascenzo, Fabrizio, D'Andrea, Natascia, Paternoster, Gianluca, Ananiadou, Sofia, Ballestra, Mariano, De Sio, Antonio, Pota, Vincenzo, Cotoia, Antonella, Selva, Andrea Della, Bruni, Andrea, Iapichino, Giacomo, Bradić, Nikola, Corradi, Francesco, Gemma, Marco, Nogtev, Pavel, Petrova, Marina, Agrò, Felice Eugenio, Cabrini, Luca, Forfori, Francesco, Likhvantsev, Valery, Bove, Tiziana, Finco, Gabriele, Landoni, Giovanni, and Zangrillo, Alberto

Subjects
medicine.medical_specialty, Randomization, Critical Care, Antibiotic resistance, Critical patients, Critical Illness, Population, meropenem, intermitent or continuous infusion, critically ill, Intensive care unit, Meropenem, Mortality, Multi-drug resistant pathogens, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Sepsis, medicine, Clinical endpoint, polycyclic compounds, Humans, Pharmacology (medical), 030212 general & internal medicine, education, Antibacterial agent, education.field_of_study, 030505 public health, Septic shock, business.industry, Critical patient, General Medicine, medicine.disease, Anti-Bacterial Agents, Emergency medicine, 0305 other medical science, business, medicine.drug
Abstract

Objective Meropenem is a β-lactam, carbapenem antibacterial agent with antimicrobial activity against gram-negative, gram-positive and anaerobic micro-organisms and is important in the empirical treatment of serious infections in Intensive Care Unit (ICU) patients. Multi-drug resistant gram-negative organisms, coupled with scarcity of new antibiotic classes, forced healthcare community to optimize the therapeutic potential of available antibiotics. Our aim is to investigate the effect of continuous infusion of meropenem against bolus administration, as indicated by a composite outcome of reducing death and emergence of extensive or pan drug-resistant pathogens in a population of ICU patients. Design Double blind, double dummy, multicenter randomized controlled trial (1:1 allocation ratio). Setting Tertiary and University hospitals. Interventions 600 ICU patients with sepsis or septic shock, needing by clinical judgment antibiotic therapy with meropenem, will be randomized to receive a continuous infusion of meropenem 3 g/24 h or an equal dose divided into three daily boluses (i.e. 1g q8h). Measurements The primary endpoint will be a composite outcome of reducing death and emergence of extensive or pan drug-resistant pathogens. Secondary endpoints will be death from any cause at day 90, antibiotic-free days at day 28, ICU-free days at day 28, cumulative SOFA-free (Sequential Organ Failure Assessment) score from randomization to day 28 and the two, separate, components of the primary endpoint. We expect a primary outcome reduction from 52 to 40% in the continuous infusion group. Conclusions The trial will provide evidence for choosing intermittent or continuous infusion of meropenem for critically ill patients with multi-drug resistant gram-negative infections.

Published
2021

20. Management of Challenging Cardiopulmonary Bypass Separation

Author

Jun Hyun Kim, Andrey Yavorovskiy, Chew Yin Wang, Nazar Bukamal, Ahmed A. Farag, Fabrizio Monaco, Giovanni Landoni, Hynek Riha, Gordana Gazivoda, Chong Lei, Marie Jo Plamondon, Mohamed R. El-Tahan, Fernanda Santos Silva, Valery V. Likhvantsev, Vladimir V. Lomivorotov, L. Sun, Ambra Licia Di Prima, Ludhmila Abrahão Hajjar, Nikola Bradic, Monaco, F., Di Prima, A. L., Kim, J. H., Plamondon, M. -J., Yavorovskiy, A., Likhvantsev, V., Lomivorotov, V., Hajjar, L. A., Landoni, G., Riha, H., Farag, A. M. G. A., Gazivoda, G., Silva, F. S., Lei, C., Bradic, N., El-Tahan, M. R., Bukamal, N. A. R., Sun, L., and Wang, C. Y.

Subjects
Inotrope, medicine.medical_specialty, separation, Ventricular Dysfunction, Right, Separation (statistics), inotropes, 030204 cardiovascular system & hematology, anesthesia, law.invention, 03 medical and health sciences, 0302 clinical medicine, 030202 anesthesiology, law, Hypovolemia, Intensive care, Vasoplegia, medicine, Cardiopulmonary bypass, Humans, Cardiac Surgical Procedures, Intensive care medicine, intensive care, Cardiopulmonary Bypass, business.industry, weaning, Thoracic Surgery, ventricular dysfunction, medicine.disease, Pulmonary hypertension, Cardiac surgery, surgical procedures, operative, Anesthesiology and Pain Medicine, medicine.symptom, Cardiology and Cardiovascular Medicine, business, cardiopulmonary bypass, Echocardiography, Transesophageal, discontinuation
Abstract

SEPARATION from cardiopulmonary bypass (CPB) after cardiac surgery is a progressive transition from full mechanical circulatory and respiratory support to spontaneous mechanical activity of the lungs and heart. During the separation phase, measurements of cardiac performance with transesophageal echocardiography (TEE) provide the rationale behind the diagnostic and therapeutic decision-making process. In many cases, it is possible to predict a complex separation from CPB, such as when there is known preoperative left or right ventricular dysfunction, bleeding, hypovolemia, vasoplegia, pulmonary hypertension, or owing to technical complications related to the surgery. Prompt diagnosis and therapeutic decisions regarding mechanical or pharmacologic support have to be made within a few minutes. In fact, a complex separation from CPB if not adequately treated leads to a poor outcome in the vast majority of cases. Unfortunately, no specific criteria defining complex separation from CPB and no management guidelines for these patients currently exist. Taking into account the above considerations, the aim of the present review is to describe the most common scenarios associated with a complex CPB separation and to suggest strategies, pharmacologic agents, and para-corporeal mechanical devices that can be adopted to manage patients with complex separation from CPB. The routine management strategies of complex CPB separation of 17 large cardiac centers from 14 countries in 5 continents will also be described.

Published
2019

21. MortalitY in caRdIAc surgery (MYRIAD):A randomizeD controlled trial of volatile anesthetics. Rationale and design

Author

Fernanda Santos Silva, Vladimir V. Lomivorotov, Samuele Frassoni, Abeer M Elnakera, Bukamal Nazar, Massimo Baiocchi, Dario Winterton, Felice Eugenio Agrò, Chong Lei, Jan Kunstyr, Luca Severi, Mohamed R. El-Tahan, Colin Royse, Evgeny Fominskiy, Rinaldo Bellomo, Vadim Pasyuga, Weiqing Huang, Jingui Yu, Antonio Pisano, Andrey Lozovskiy, Fabio Guarracino, Cristiana Carollo, Giuseppe Crescenzi, Marco Gemma, Jun Ma, Sidik Hanafi, Laura Ruggeri, Hynek Riha, Caetano Nigro Neto, Rosalba Lembo, Zhi jian Li, Gordana Gazivoda, Andrei Bautin, Filomena Regina Barbosa Gomes Galas, Chow Yen Yong, Ahmed G. Farag, Stefano Gianni, Nikola Bradic, Umberto Benedetto, Alberto Zangrillo, Paolo Navalesi, Cheng Bin Wang, Giovanni Landoni, Nikolay S Uvaliev, Gudrun Kunst, Vladimir Shmyrev, Valery Likhvantsev, Giuseppe Biondi Zoccai, Chew Yin Wang, Evgeny Grigoryev, Fabrizio Monaco, Elena Porteri, Landoni, Giovanni, Lomivorotov, Vladimir, Pisano, Antonio, Nigro Neto, Caetano, Benedetto, Umberto, Biondi Zoccai, Giuseppe, Gemma, Marco, Frassoni, Samuele, Agrò, Felice Eugenio, Baiocchi, Massimo, Barbosa Gomes Galas, Filomena R., Bautin, Andrei, Bradic, Nikola, Carollo, Cristiana, Crescenzi, Giuseppe, Elnakera, Abeer M., El Tahan, Mohamed R., Fominskiy, Evgeny, Farag, Ahmed G., Gazivoda, Gordana, Gianni, Stefano, Grigoryev, Evgeny, Guarracino, Fabio, Hanafi, Sidik, Huang, Weiqing, Kunst, Gudrun, Kunstyr, Jan, Lei, Chong, Lembo, Rosalba, Li, Zhi jian, Likhvantsev, Valery, Lozovskiy, Andrey, Ma, Jun, Monaco, Fabrizio, Navalesi, Paolo, Nazar, Bukamal, Pasyuga, Vadim, Porteri, Elena, Royse, Colin, Ruggeri, Laura, Riha, Hynek, Santos Silva, Fernanda, Severi, Luca, Shmyrev, Vladimir, Uvaliev, Nikolay, Wang, Cheng Bin, Wang, Chew Yin, Winterton, Dario, Yong, Chow Yen, Yu, Jingui, Bellomo, Rinaldo, Zangrillo, Alberto, Landoni, G, Lomivorotov, V, Pisano, A, Nigro Neto, C, Benedetto, U, Biondi Zoccai, G, Gemma, M, Frassoni, S, Agro, F, Baiocchi, M, Barbosa Gomes Galas, F, Bautin, A, Bradic, N, Carollo, C, Crescenzi, G, Elnakera, A, El-Tahan, M, Fominskiy, E, Farag, A, Gazivoda, G, Gianni, S, Grigoryev, E, Guarracino, F, Hanafi, S, Huang, W, Kunst, G, Kunstyr, J, Lei, C, Lembo, R, Li, Z, Likhvantsev, V, Lozovskiy, A, Ma, J, Monaco, F, Navalesi, P, Nazar, B, Pasyuga, V, Porteri, E, Royse, C, Ruggeri, L, Riha, H, Santos Silva, F, Severi, L, Shmyrev, V, Uvaliev, N, Wang, C, Winterton, D, Yong, C, Yu, J, Bellomo, R, and Zangrillo, A

Subjects
Adult, Male, Total intravenous anesthesia, Coronary Artery Disease, 030204 cardiovascular system & hematology, law.invention, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Randomized controlled trial, law, Intensive care, medicine, Clinical endpoint, Anesthesia, Cardiac Procedures, Humans, Pharmacology (medical), 030212 general & internal medicine, Myocardial infarction, Coronary Artery Bypass, Cardiac anesthesia, Cardiac surgery, Randomized trial, Volatile anesthetics, business.industry, Coronary Artery Bypa, Medicine (all), General Medicine, medicine.disease, Intensive care unit, Survival Analysis, Volatile anesthetic, Outcome and Process Assessment, Health Care, Intravenous anesthesia, Anesthesia, Anesthetic, Anesthetics, Inhalation, Female, Survival Analysi, Volatilization, business, Anesthesia, Cardiac Procedure, Human, medicine.drug
Abstract

Objective There is initial evidence that the use of volatile anesthetics can reduce the postoperative release of cardiac troponin I, the need for inotropic support, and the number of patients requiring prolonged hospitalization following coronary artery bypass graft (CABG) surgery. Nevertheless, small randomized controlled trials have failed to demonstrate a survival advantage. Thus, whether volatile anesthetics improve the postoperative outcome of cardiac surgical patients remains uncertain. An adequately powered randomized controlled trial appears desirable. Design Single blinded, international, multicenter randomized controlled trial with 1:1 allocation ratio. Setting Tertiary and University hospitals. Interventions Patients (n = 10,600) undergoing coronary artery bypass graft will be randomized to receive either volatile anesthetic as part of the anesthetic plan, or total intravenous anesthesia. Measurements and main results The primary end point of the study will be one-year mortality (any cause). Secondary endpoints will be 30-day mortality; 30-day death or non-fatal myocardial infarction (composite endpoint); cardiac mortality at 30 day and at one year; incidence of hospital re-admission during the one year follow-up period and duration of intensive care unit, and hospital stay. The sample size is based on the hypothesis that volatile anesthetics will reduce 1-year unadjusted mortality from 3% to 2%, using a two-sided alpha error of 0.05, and a power of 0.9. Conclusions The trial will determine whether the simple intervention of adding a volatile anesthetic, an intervention that can be implemented by all anesthesiologists, can improve one-year survival in patients undergoing coronary artery bypass graft surgery.

Published
2017

22. A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design

Author

Rosalba Lembo, Marco Gemma, Massimo Baiocchi, Giuseppe Biondi-Zoccai, Rosetta Lobreglio, Claudia Cariello, Giovanni De Vuono, Gianluca Paternoster, Fabrizio Monaco, Vladimir V. Lomivorotov, Alberto Zangrillo, Alessandro Bianchi, Evgeny Grigoryev, Maria Chiara Zucchetti, Valery Likhvantsev, Michael J. Lipinski, Tiziana Bove, Fabio Guarracino, Stefano Gianni, Antonio Pisano, Stefano Auriemma, Fabio Sangalli, Mario Frontini, Gabriele Alvaro, Maria Grazia Calabrò, Giovanni Landoni, Giovanni Pala, Nikola Bradic, Chew Yin Wang, Elisabetta Auci, Antonio Corcione, Evgeny Fominskiy, Nicola Galdieri, Bruno Amantea, Giuseppe Buscaglia, Zangrillo, Alberto, Alvaro, G, Pisano, A, Guarracino, F, Lobreglio, R, Bradic, N, Lembo, R, Gianni, S, Calabrò, Mg, Likhvantsev, V, Grigoryev, E, Buscaglia, G, Pala, G, Auci, E, Amantea, B, Monaco, F, De Vuono, G, Corcione, A, Galdieri, N, Cariello, C, Bove, T, Fominskiy, E, Auriemma, S, Baiocchi, M, Bianchi, A, Frontini, M, Paternoster, G, Sangalli, F, Wang, Cy, Zucchetti, Mc, Biondi Zoccai, G, Gemma, M, Lipinski, Mj, Lomivorotov, Vv, and Landoni, Giovanni

Subjects
Infusions, Cardiac output, medicine.medical_specialty, Cardiotonic Agents, Cardiac Output, Low, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Randomized controlled trial, Double-Blind Method, law, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Cardiac Output, Cardiac Surgical Procedures, Infusions, Intravenous, Simendan, Intra-Aortic Balloon Pumping, business.industry, Respiration, Hydrazones, Levosimendan, Perioperative, Acute Kidney Injury, Length of Stay, Intensive care unit, Respiration, Artificial, Low, Cardiac surgery, Pyridazines, Intensive Care Units, Artificial, Cardiology and Cardiovascular Medicine, Cardiology, Intravenous, business, medicine.drug
Abstract

Objective Patients undergoing cardiac surgery are at risk of perioperative low cardiac output syndrome due to postoperative myocardial dysfunction. Myocardial dysfunction in patients undergoing cardiac surgery is a potential indication for the use of levosimendan, a calcium sensitizer with 3 beneficial cardiovascular effects (inotropic, vasodilatory, and anti-inflammatory), which appears effective in improving clinically relevant outcomes. Design Double-blind, placebo-controlled, multicenter randomized trial. Setting Tertiary care hospitals. Interventions Cardiac surgery patients (n = 1,000) with postoperative myocardial dysfunction (defined as patients with intraaortic balloon pump and/or high-dose standard inotropic support) will be randomized to receive a continuous infusion of either levosimendan (0.05-0.2 μg/[kg min]) or placebo for 24-48 hours. Measurements and main results The primary end point will be 30-day mortality. Secondary end points will be mortality at 1 year, time on mechanical ventilation, acute kidney injury, decision to stop the study drug due to adverse events or to start open-label levosimendan, and length of intensive care unit and hospital stay. We will test the hypothesis that levosimendan reduces 30-day mortality in cardiac surgery patients with postoperative myocardial dysfunction. Conclusions This trial is planned to determine whether levosimendan could improve survival in patients with postoperative low cardiac output syndrome. The results of this double-blind, placebo-controlled randomized trial may provide important insights into the management of low cardiac output in cardiac surgery.

Published
2015

23. High dose esomeprazole as an anti-inflammatory agent in sepsis: Protocol for a randomized controlled trial.

Author

Monti G, Konkayev A, Carta S, Bradic N, Bruni A, Kotani Y, Guarracino F, Redkin I, Biondi-Zoccai G, Benedetto U, D'Ascenzo F, Garofalo E, Baiardo Redaelli M, Brizzi G, Forfori F, Borghi G, Scapol S, Momesso E, Cuffaro R, Boffa N, Rauch S, D'Amico F, Montrucchio G, Pace MC, Galbiati C, Bosso S, Savelli F, Giardina G, Silvetti S, Tripodi VF, Labanca R, Lembo R, Marmiere M, Marzaroli M, Nakhnoukh C, Valsecchi D, Finco G, Agrò FE, Bove T, Corradi F, Longhini F, Landoni G, Bellomo R, and Zangrillo A

Abstract

Background: Sepsis is caused by dysregulated immune responses due to infection and still presents high mortality rate and limited efficacious therapies, apart from antibiotics. Recent evidence suggests that very high dose proton pump inhibitors might regulate major sepsis mediators' secretion by monocytes, which might attenuate excessive host reactions and improve clinical outcomes. This effect is obtained with doses which are approximately 50 times higher than prophylactic esomeprazole single daily administration and 17 times higher than the cumulative dose of a three day prophylaxis. We aim to perform a randomized trial to investigate if high dose esomeprazole reduces organ dysfunction in patients with sepsis or septic shock., Methods: This study, called PPI-SEPSIS, is a multicenter, randomized, double blind, placebo-controlled clinical trial on critically ill septic patients admitted to the emergency department or intensive care unit. A total of 300 patients will be randomized to receive high dose esomeprazole (80 mg bolus followed by 12 mg/h for 72 h and a second 80 mg bolus 12 h after the first one) or equivolume placebo (sodium chloride 0.9%), with 1:1 allocation. The primary endpoint of the study will be mean daily Sequential Organ Failure Assessment (SOFA) score over 10 days. Secondary outcomes will include antibiotic-free days, single organ failure severity, intensive care unit-free days at day 28, and mortality., Discussion: This trial aims to test the efficacy of high dose esomeprazole to reduce acute organ dysfunction in patients with septic shock., Trial Registration: This trial was registered on ClinicalTrials.gov with the trial identification NCT03452865 in March 2018., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

24. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.

Author

Monti G, Bradic N, Marzaroli M, Konkayev A, Fominskiy E, Kotani Y, Likhvantsev VV, Momesso E, Nogtev P, Lobreglio R, Redkin I, Toffoletto F, Bruni A, Baiardo Redaelli M, D'Andrea N, Paternoster G, Scandroglio AM, Gallicchio F, Ballestra M, Calabrò MG, Cotoia A, Perone R, Cuffaro R, Montrucchio G, Pota V, Ananiadou S, Lembo R, Musu M, Rauch S, Galbiati C, Pinelli F, Pasin L, Guarracino F, Santarpino G, Agrò FE, Bove T, Corradi F, Forfori F, Longhini F, Cecconi M, Landoni G, Bellomo R, and Zangrillo A

Subjects
Humans, Female, Middle Aged, Male, Meropenem therapeutic use, Critical Illness therapy, Double-Blind Method, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents administration & dosage, Monobactams therapeutic use, Shock, Septic mortality, Sepsis complications, Hypersensitivity
Abstract

Importance: Meropenem is a widely prescribed β-lactam antibiotic. Meropenem exhibits maximum pharmacodynamic efficacy when given by continuous infusion to deliver constant drug levels above the minimal inhibitory concentration. Compared with intermittent administration, continuous administration of meropenem may improve clinical outcomes., Objective: To determine whether continuous administration of meropenem reduces a composite of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria compared with intermittent administration in critically ill patients with sepsis., Design, Setting, and Participants: A double-blind, randomized clinical trial enrolling critically ill patients with sepsis or septic shock who had been prescribed meropenem by their treating clinicians at 31 intensive care units of 26 hospitals in 4 countries (Croatia, Italy, Kazakhstan, and Russia). Patients were enrolled between June 5, 2018, and August 9, 2022, and the final 90-day follow-up was completed in November 2022., Interventions: Patients were randomized to receive an equal dose of the antibiotic meropenem by either continuous administration (n = 303) or intermittent administration (n = 304)., Main Outcomes and Measures: The primary outcome was a composite of all-cause mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28. There were 4 secondary outcomes, including days alive and free from antibiotics at day 28, days alive and free from the intensive care unit at day 28, and all-cause mortality at day 90. Seizures, allergic reactions, and mortality were recorded as adverse events., Results: All 607 patients (mean age, 64 [SD, 15] years; 203 were women [33%]) were included in the measurement of the 28-day primary outcome and completed the 90-day mortality follow-up. The majority (369 patients, 61%) had septic shock. The median time from hospital admission to randomization was 9 days (IQR, 3-17 days) and the median duration of meropenem therapy was 11 days (IQR, 6-17 days). Only 1 crossover event was recorded. The primary outcome occurred in 142 patients (47%) in the continuous administration group and in 149 patients (49%) in the intermittent administration group (relative risk, 0.96 [95% CI, 0.81-1.13], P = .60). Of the 4 secondary outcomes, none was statistically significant. No adverse events of seizures or allergic reactions related to the study drug were reported. At 90 days, mortality was 42% both in the continuous administration group (127 of 303 patients) and in the intermittent administration group (127 of 304 patients)., Conclusions and Relevance: In critically ill patients with sepsis, compared with intermittent administration, the continuous administration of meropenem did not improve the composite outcome of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28., Trial Registration: ClinicalTrials.gov Identifier: NCT03452839.

Published
2023
Full Text
View/download PDF

25. Effect of Volatile Anesthetics on Myocardial Infarction After Coronary Artery Surgery: A Post Hoc Analysis of a Randomized Trial.

Author

Zangrillo A, Lomivorotov VV, Pasyuga VV, Belletti A, Gazivoda G, Monaco F, Nigro Neto C, Likhvantsev VV, Bradic N, Lozovskiy A, Lei C, Bukamal NAR, Silva FS, Bautin AE, Ma J, Yong CY, Carollo C, Kunstyr J, Wang CY, Grigoryev EV, Riha H, Wang C, El-Tahan MR, Scandroglio AM, Mansor M, Lembo R, Ponomarev DN, Bezerra FJL, Ruggeri L, Chernyavskiy AM, Xu J, Tarasov DG, Navalesi P, Yavorovskiy A, Bove T, Kuzovlev A, Hajjar LA, and Landoni G

Subjects
Aged, Anesthetics, Intravenous, Coronary Artery Bypass methods, Humans, Middle Aged, Postoperative Complications diagnosis, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Sevoflurane, Anesthetics, Inhalation, Myocardial Infarction drug therapy, Myocardial Infarction epidemiology, Propofol
Abstract

Objective: To investigate the effect of volatile anesthetics on the rates of postoperative myocardial infarction (MI) and cardiac death after coronary artery bypass graft (CABG)., Design: A post hoc analysis of a randomized trial., Setting: Cardiac surgical operating rooms., Participants: Patients undergoing elective, isolated CABG., Interventions: Patients were randomized to receive a volatile anesthetic (desflurane, isoflurane, or sevoflurane) or total intravenous anesthesia (TIVA). The primary outcome was hemodynamically relevant MI (MI requiring high-dose inotropic support or prolonged intensive care unit stay) occurring within 48 hours from surgery. The secondary outcome was 1-year death due to cardiac causes., Measurements and Main Results: A total of 5,400 patients were enrolled between April 2014 and September 2017 (2,709 patients randomized to the volatile anesthetics group and 2,691 to TIVA). The mean age was 62 ± 8.4 years, and the median baseline ejection fraction was 57% (50-67), without differences between the 2 groups. Patients in the volatile group had a lower incidence of MI with hemodynamic complications both in the per-protocol (14 of 2,530 [0.6%] v 27 of 2,501 [1.1%] in the TIVA group; p = 0.038) and as-treated analyses (16 of 2,708 [0.6%] v 29 of 2,617 [1.1%] in the TIVA group; p = 0.039), but not in the intention-to-treat analysis (17 of 2,663 [0.6%] v 28 of 2,667 [1.0%] in the TIVA group; p = 0.10). Overall, deaths due to cardiac causes were lower in the volatile group (23 of 2,685 [0.9%] v 40 of 2,668 [1.5%] than in the TIVA group; p = 0.03)., Conclusions: An anesthetic regimen, including volatile agents, may be associated with a lower rate of postoperative MI with hemodynamic complication in patients undergoing CABG. Furthermore, it may reduce long-term cardiac mortality., Competing Interests: Declaration of Competing Interest V.V.L. received a speaking honorarium from Baxter., (Copyright © 2022 Elsevier Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

26. EASAPS/ESPRAS Considerations in getting back to work in Plastic Surgery with the COVID-19 Pandemic - A European point of view.

Author

van Heijningen I, Frank K, Almeida F, Bösch U, Bradic N, Costa H, Demirdover C, Henley M, Kamolz LP, Rouif M, Spendel S, Russe-Wilflingseder K, Stark B, Giunta RE, Parreira JC, and Zic R

Subjects
Betacoronavirus, COVID-19, Esthetics, Europe, Humans, Pandemics, SARS-CoV-2, Coronavirus Infections epidemiology, Pneumonia, Viral epidemiology, Return to Work, Surgery, Plastic
Abstract

The aim of this paper is to summarize the results of a consensus process and a European webinar of the two societies, European Association of Societies of Aesthetic Surgery (EASAPS) and the European Society of Plastic, Reconstructive and Aesthetic Societies (ESPRAS) on what is considered safe practice based on the scientific knowledge we have today. This review of the current situations gives considerations which have to be taken into account when getting back to work in plastic surgery with COVID-19 in Europe. At all times, one should be familiar the local and regional infection rates in the community, with particular emphasis on the emergence of second and third waves of the pandemic. Due to the fast-evolving nature of the COVID-19 pandemic the recommendations aim to be rather considerations than fixed guidelines and might need to be revised in near future., Competing Interests: None of the other authors listed have any commercial associations or financial disclosures that might pose or create a conflict of interest with the methods applied or the results presented in this article., (© Georg Thieme Verlag KG Stuttgart · New York.)

Published
2020
Full Text
View/download PDF

27. A Systematic Review and International Web-Based Survey of Randomized Controlled Trials in the Perioperative and Critical Care Setting: Interventions Increasing Mortality.

Author

Sartini C, Lomivorotov V, Pisano A, Riha H, Baiardo Redaelli M, Lopez-Delgado JC, Pieri M, Hajjar L, Fominskiy E, Likhvantsev V, Cabrini L, Bradic N, Avancini D, Wang CY, Lembo R, Novikov M, Paternoster G, Gazivoda G, Alvaro G, Roasio A, Wang C, Severi L, Pasin L, Mura P, Musu M, Silvetti S, Votta CD, Belletti A, Corradi F, Brusasco C, Tamà S, Ruggeri L, Yong CY, Pasero D, Mancino G, Spadaro S, Conte M, Lobreglio R, Di Fraja D, Saporito E, D'Amico A, Sardo S, Ortalda A, Yavorovskiy A, Riefolo C, Monaco F, Bellomo R, Zangrillo A, and Landoni G

Subjects
Cardiac Surgical Procedures adverse effects, Cardiac Surgical Procedures mortality, Critical Illness therapy, Humans, Internet, Mortality trends, Critical Care methods, Critical Illness mortality, Perioperative Care methods, Physicians, Randomized Controlled Trials as Topic methods, Surveys and Questionnaires
Abstract

Objective: Reducing mortality is a key target in critical care and perioperative medicine. The authors aimed to identify all nonsurgical interventions (drugs, techniques, strategies) shown by randomized trials to increase mortality in these clinical settings., Design: A systematic review of the literature followed by a consensus-based voting process., Setting: A web-based international consensus conference., Participants: Two hundred fifty-one physicians from 46 countries., Interventions: The authors performed a systematic literature search and identified all randomized controlled trials (RCTs) showing a significant increase in unadjusted landmark mortality among surgical or critically ill patients. The authors reviewed such studies during a meeting by a core group of experts. Studies selected after such review advanced to web-based voting by clinicians in relation to agreement, clinical practice, and willingness to include each intervention in international guidelines., Measurements and Main Results: The authors selected 12 RCTs dealing with 12 interventions increasing mortality: diaspirin-crosslinked hemoglobin (92% of agreement among web voters), overfeeding, nitric oxide synthase inhibitor in septic shock, human growth hormone, thyroxin in acute kidney injury, intravenous salbutamol in acute respiratory distress syndrome, plasma-derived protein C concentrate, aprotinin in high-risk cardiac surgery, cysteine prodrug, hypothermia in meningitis, methylprednisolone in traumatic brain injury, and albumin in traumatic brain injury (72% of agreement). Overall, a high consistency (ranging from 80% to 90%) between agreement and clinical practice was observed., Conclusion: The authors identified 12 clinical interventions showing increased mortality supported by randomized controlled trials with nonconflicting evidence, and wide agreement upon clinicians on a global scale., (Copyright © 2019 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

28. A Systematic Review and International Web-Based Survey of Randomized Controlled Trials in the Perioperative and Critical Care Setting: Interventions Reducing Mortality.

Author

Sartini C, Lomivorotov V, Pieri M, Lopez-Delgado JC, Baiardo Redaelli M, Hajjar L, Pisano A, Likhvantsev V, Fominskiy E, Bradic N, Cabrini L, Novikov M, Avancini D, Riha H, Lembo R, Gazivoda G, Paternoster G, Wang C, Tamà S, Alvaro G, Wang CY, Roasio A, Ruggeri L, Yong CY, Pasero D, Severi L, Pasin L, Mancino G, Mura P, Musu M, Spadaro S, Conte M, Lobreglio R, Silvetti S, Votta CD, Belletti A, Di Fraja D, Corradi F, Brusasco C, Saporito E, D'Amico A, Sardo S, Ortalda A, Riefolo C, Fabrizio M, Zangrillo A, Bellomo R, and Landoni G

Subjects
Critical Care trends, Critical Illness therapy, Humans, Intensive Care Units trends, Mortality trends, Critical Care methods, Critical Illness mortality, Internet trends, Physicians trends, Randomized Controlled Trials as Topic methods, Surveys and Questionnaires
Abstract

The authors aimed to identify interventions documented by randomized controlled trials (RCTs) that reduce mortality in adult critically ill and perioperative patients, followed by a survey of clinicians' opinions and routine practices to understand the clinicians' response to such evidence. The authors performed a comprehensive literature review to identify all topics reported to reduce mortality in perioperative and critical care settings according to at least 2 RCTs or to a multicenter RCT or to a single-center RCT plus guidelines. The authors generated position statements that were voted on online by physicians worldwide for agreement, use, and willingness to include in international guidelines. From 262 RCT manuscripts reporting mortality differences in the perioperative and critically ill settings, the authors selected 27 drugs, techniques, and strategies (66 RCTs, most frequently published by the New England Journal of Medicine [13 papers], Lancet [7], and Journal of the American Medical Association [5]) with an agreement ≥67% from over 250 physicians (46 countries). Noninvasive ventilation was the intervention supported by the largest number of RCTs (n = 13). The concordance between agreement and use (a positive answer both to "do you agree" and "do you use") showed differences between Western and other countries and between anesthesiologists and intensive care unit physicians. The authors identified 27 clinical interventions with randomized evidence of survival benefit and strong clinician support in support of their potential life-saving properties in perioperative and critically ill patients with noninvasive ventilation having the highest level of support. However, clinician views appear affected by specialty and geographical location., (Copyright © 2018 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

29. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery.

Author

Landoni G, Lomivorotov VV, Nigro Neto C, Monaco F, Pasyuga VV, Bradic N, Lembo R, Gazivoda G, Likhvantsev VV, Lei C, Lozovskiy A, Di Tomasso N, Bukamal NAR, Silva FS, Bautin AE, Ma J, Crivellari M, Farag AMGA, Uvaliev NS, Carollo C, Pieri M, Kunstýř J, Wang CY, Belletti A, Hajjar LA, Grigoryev EV, Agrò FE, Riha H, El-Tahan MR, Scandroglio AM, Elnakera AM, Baiocchi M, Navalesi P, Shmyrev VA, Severi L, Hegazy MA, Crescenzi G, Ponomarev DN, Brazzi L, Arnoni R, Tarasov DG, Jovic M, Calabrò MG, Bove T, Bellomo R, and Zangrillo A

Subjects
Administration, Inhalation, Aged, Anesthesia, General, Anesthetics, Intravenous, Coronary Artery Disease mortality, Coronary Artery Disease physiopathology, Elective Surgical Procedures, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mortality, Single-Blind Method, Stroke Volume, Anesthesia, Intravenous, Anesthetics, General pharmacology, Coronary Artery Bypass, Coronary Artery Disease surgery
Abstract

Background: Volatile (inhaled) anesthetic agents have cardioprotective effects, which might improve clinical outcomes in patients undergoing coronary-artery bypass grafting (CABG)., Methods: We conducted a pragmatic, multicenter, single-blind, controlled trial at 36 centers in 13 countries. Patients scheduled to undergo elective CABG were randomly assigned to an intraoperative anesthetic regimen that included a volatile anesthetic (desflurane, isoflurane, or sevoflurane) or to total intravenous anesthesia. The primary outcome was death from any cause at 1 year., Results: A total of 5400 patients were randomly assigned: 2709 to the volatile anesthetics group and 2691 to the total intravenous anesthesia group. On-pump CABG was performed in 64% of patients, with a mean duration of cardiopulmonary bypass of 79 minutes. The two groups were similar with respect to demographic and clinical characteristics at baseline, the duration of cardiopulmonary bypass, and the number of grafts. At the time of the second interim analysis, the data and safety monitoring board advised that the trial should be stopped for futility. No significant difference between the groups with respect to deaths from any cause was seen at 1 year (2.8% in the volatile anesthetics group and 3.0% in the total intravenous anesthesia group; relative risk, 0.94; 95% confidence interval [CI], 0.69 to 1.29; P = 0.71), with data available for 5353 patients (99.1%), or at 30 days (1.4% and 1.3%, respectively; relative risk, 1.11; 95% CI, 0.70 to 1.76), with data available for 5398 patients (99.9%). There were no significant differences between the groups in any of the secondary outcomes or in the incidence of prespecified adverse events, including myocardial infarction., Conclusions: Among patients undergoing elective CABG, anesthesia with a volatile agent did not result in significantly fewer deaths at 1 year than total intravenous anesthesia. (Funded by the Italian Ministry of Health; MYRIAD ClinicalTrials.gov number, NCT02105610.)., (Copyright © 2019 Massachusetts Medical Society.)

Published
2019
Full Text
View/download PDF

30. Surgery and discontinuation of angiotensin converting enzyme inhibitors: current perspectives.

Author

Bradic N and Povsic-Cevra Z

Subjects
Anesthesia, Angiotensin Receptor Antagonists adverse effects, Humans, Hypotension chemically induced, Angiotensin-Converting Enzyme Inhibitors adverse effects, Perioperative Care
Abstract

Purpose of Review: The current article reviews the current evidence for continuing or discontinuing angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) during the perioperative period., Recent Findings: In patients undergoing treatment of hypertension with ACEIs or ARBs, there are both benefits associated with continuing these medications during the perioperative period and higher risk for perioperative hypotension and its complications., Summary: Since the introduction of ACEIs and ARBs into clinical practice, their use during the perioperative period has been controversial. Although these medications increase the risk of serious hypotension immediately after induction and maintenance of anesthesia, their use has numerous benefits, making it reasonable to continue them during perioperative period.

Published
2018
Full Text
View/download PDF

31. MortalitY in caRdIAc surgery (MYRIAD): A randomizeD controlled trial of volatile anesthetics. Rationale and design.

Author

Landoni G, Lomivorotov V, Pisano A, Nigro Neto C, Benedetto U, Biondi Zoccai G, Gemma M, Frassoni S, Agrò FE, Baiocchi M, Barbosa Gomes Galas FR, Bautin A, Bradic N, Carollo C, Crescenzi G, Elnakera AM, El-Tahan MR, Fominskiy E, Farag AG, Gazivoda G, Gianni S, Grigoryev E, Guarracino F, Hanafi S, Huang W, Kunst G, Kunstyr J, Lei C, Lembo R, Li ZJ, Likhvantsev V, Lozovskiy A, Ma J, Monaco F, Navalesi P, Nazar B, Pasyuga V, Porteri E, Royse C, Ruggeri L, Riha H, Santos Silva F, Severi L, Shmyrev V, Uvaliev N, Wang CB, Wang CY, Winterton D, Yong CY, Yu J, Bellomo R, and Zangrillo A

Subjects
Adult, Coronary Artery Disease mortality, Female, Humans, Male, Outcome and Process Assessment, Health Care, Survival Analysis, Volatilization, Anesthesia, Cardiac Procedures adverse effects, Anesthesia, Cardiac Procedures methods, Anesthetics, Inhalation administration & dosage, Anesthetics, Inhalation chemistry, Coronary Artery Bypass adverse effects, Coronary Artery Bypass methods, Coronary Artery Bypass mortality, Coronary Artery Disease surgery, Postoperative Complications etiology, Postoperative Complications prevention & control
Abstract

Objective: There is initial evidence that the use of volatile anesthetics can reduce the postoperative release of cardiac troponin I, the need for inotropic support, and the number of patients requiring prolonged hospitalization following coronary artery bypass graft (CABG) surgery. Nevertheless, small randomized controlled trials have failed to demonstrate a survival advantage. Thus, whether volatile anesthetics improve the postoperative outcome of cardiac surgical patients remains uncertain. An adequately powered randomized controlled trial appears desirable., Design: Single blinded, international, multicenter randomized controlled trial with 1:1 allocation ratio., Setting: Tertiary and University hospitals., Interventions: Patients (n=10,600) undergoing coronary artery bypass graft will be randomized to receive either volatile anesthetic as part of the anesthetic plan, or total intravenous anesthesia., Measurements and Main Results: The primary end point of the study will be one-year mortality (any cause). Secondary endpoints will be 30-day mortality; 30-day death or non-fatal myocardial infarction (composite endpoint); cardiac mortality at 30day and at one year; incidence of hospital re-admission during the one year follow-up period and duration of intensive care unit, and hospital stay. The sample size is based on the hypothesis that volatile anesthetics will reduce 1-year unadjusted mortality from 3% to 2%, using a two-sided alpha error of 0.05, and a power of 0.9., Conclusions: The trial will determine whether the simple intervention of adding a volatile anesthetic, an intervention that can be implemented by all anesthesiologists, can improve one-year survival in patients undergoing coronary artery bypass graft surgery., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

32. Successful treatment of annular rupture during transcatheter aortic valve implantation.

Author

Unic D, Sutlic Z, Starcevic B, Bradic N, Baric D, and Rudez I

Subjects
Aged, 80 and over, Female, Humans, Reoperation methods, Treatment Outcome, Aortic Valve injuries, Aortic Valve surgery, Cardiac Valve Annuloplasty methods, Rupture etiology, Rupture surgery, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement methods
Abstract

Annular rupture presents a rare but potentially fatal complication of transcatheter aortic valve implantation (TAVI). Although it can be subtle and subclinical in presentation, most severe forms present with hemodynamic instability and represent true emergencies requiring a more invasive treatment, even conventional surgery. We present a case of successful treatment of annular rupture by left ventricular outflow tract patch and surgical aortic valve replacement.

Published
2017
Full Text
View/download PDF

33. A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design.

Author

Zangrillo A, Alvaro G, Pisano A, Guarracino F, Lobreglio R, Bradic N, Lembo R, Gianni S, Calabrò MG, Likhvantsev V, Grigoryev E, Buscaglia G, Pala G, Auci E, Amantea B, Monaco F, De Vuono G, Corcione A, Galdieri N, Cariello C, Bove T, Fominskiy E, Auriemma S, Baiocchi M, Bianchi A, Frontini M, Paternoster G, Sangalli F, Wang CY, Zucchetti MC, Biondi-Zoccai G, Gemma M, Lipinski MJ, Lomivorotov VV, and Landoni G

Subjects
Acute Kidney Injury epidemiology, Cardiac Output, Low mortality, Cardiac Surgical Procedures mortality, Double-Blind Method, Humans, Infusions, Intravenous, Intensive Care Units, Length of Stay statistics & numerical data, Postoperative Complications mortality, Respiration, Artificial, Simendan, Cardiac Output, Low therapy, Cardiotonic Agents therapeutic use, Hydrazones therapeutic use, Intra-Aortic Balloon Pumping, Postoperative Complications therapy, Pyridazines therapeutic use
Abstract

Objective: Patients undergoing cardiac surgery are at risk of perioperative low cardiac output syndrome due to postoperative myocardial dysfunction. Myocardial dysfunction in patients undergoing cardiac surgery is a potential indication for the use of levosimendan, a calcium sensitizer with 3 beneficial cardiovascular effects (inotropic, vasodilatory, and anti-inflammatory), which appears effective in improving clinically relevant outcomes., Design: Double-blind, placebo-controlled, multicenter randomized trial., Setting: Tertiary care hospitals., Interventions: Cardiac surgery patients (n = 1,000) with postoperative myocardial dysfunction (defined as patients with intraaortic balloon pump and/or high-dose standard inotropic support) will be randomized to receive a continuous infusion of either levosimendan (0.05-0.2 μg/[kg min]) or placebo for 24-48 hours., Measurements and Main Results: The primary end point will be 30-day mortality. Secondary end points will be mortality at 1 year, time on mechanical ventilation, acute kidney injury, decision to stop the study drug due to adverse events or to start open-label levosimendan, and length of intensive care unit and hospital stay. We will test the hypothesis that levosimendan reduces 30-day mortality in cardiac surgery patients with postoperative myocardial dysfunction., Conclusions: This trial is planned to determine whether levosimendan could improve survival in patients with postoperative low cardiac output syndrome. The results of this double-blind, placebo-controlled randomized trial may provide important insights into the management of low cardiac output in cardiac surgery., (Copyright © 2016 Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

34. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

Author

Bove T, Matteazzi A, Belletti A, Paternoster G, Saleh O, Taddeo D, Dossi R, Greco T, Bradic N, Husedzinovic I, Nigro Neto C, Lomivorotov VV, and Calabrò MG

Abstract

Introduction: The incidence of Acute Kidney Injury is nowadays high in critically ill patients. Its etiology is multifactorial and a primary role is played by low cardiac output syndrome. Everything targeted to normalize cardiac output should increase the renal perfusion and abolish the secondary vasoconstriction. Levosimendan is a calcium sensitizer drug with inotropic properties that improves cardiac output and seems to increase renal blood flow. The aim of this meta-analysis was to evaluate the role of levosimendan in critically ill patients with or at risk of Acute Kidney Injury., Methods: We performed a meta-analysis of  randomized controlled trials searching for trials that compared levosimendan with any comparator. The endpoints were the number of patients receiving Renal Replacement Therapy after randomization and the number of patients developing Acute Kidney Injury., Results: Final analysis included 33 trials and 3,879 patients (2,024 levosimendan and 1,855 control). The overall analysis showed that the use of levosimendan was associated with a significant reduction in the risk of Renal Replacement Therapy (17 of 492 [3.5%] in the levosimendan group versus 37 of 427 [8.7%] in the control group, relative risk =0.52 [0.32 to 0.86], p for effect =0.01) and of Acute Kidney Injury (114 of 1,598 [7.1%] in the levosimendan group versus 143 of 1,529 [9.4%] in the control arm, relative risk =0.79 [0.63 to 0.99], p for effect =0.048)., Conclusions: This meta-analysis suggests that the use of levosimendan is associated with a significant reduction of Renal Replacement Therapy in critically ill patients.

Published
2015

35. Hemodynamic response to moderate dobutamine dose in OPCAB during acute normovolemic hemodilution.

Author

Tonkovic D, Husedzinovic I, Barisin S, Bradic N, Schmidt S, and Barisin A

Subjects
Adrenergic beta-Agonists administration & dosage, Anesthesia, Dobutamine administration & dosage, Humans, Infusions, Intravenous, Oxygen Consumption drug effects, Adrenergic beta-Agonists pharmacology, Coronary Artery Bypass, Off-Pump, Dobutamine pharmacology, Hemodilution, Hemodynamics drug effects
Published
2005
Full Text
View/download PDF

36. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study.

Author

Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, and Tonkovic D

Subjects
Anesthesia, Angiotensin-Converting Enzyme Inhibitors pharmacology, Cardiovascular Diseases surgery, Dose-Response Relationship, Drug, Double-Blind Method, Female, Hemodynamics drug effects, Humans, Male, Middle Aged, Monitoring, Intraoperative, Simendan, Ventricular Function, Left drug effects, Cardiotonic Agents therapeutic use, Coronary Artery Bypass, Hydrazones therapeutic use, Pyridazines therapeutic use
Abstract

We tested the hypothesis that levosimendan produced beneficial hemodynamic effects during and after off-pump coronary artery bypass grafting in patients with good preoperative left ventricular function. Levosimendan at low dose (12 microg/kg), high dose (24 microg/kg), or placebo were administered in thirty-one patients in a randomized and four-times masked controlled study. Heart rate was not significantly different between experimental groups. Significant increases in cardiac output and left ventricular ejection fraction occurred after high-dose (P < 0.001; P = 0.006) and low-dose levosimendan (P = 0.001; P = 0.002). Both doses of levosimendan produced significant increased stroke volume and decreased systemic vascular resistance. Mean arterial pressure, pulmonary capillary wedge pressure, and left ventricular end-systolic volume were not significantly different between groups. The low-dose levosimendan produced better hemodynamic response than high-dose and may be preferable in patients undergoing off-pump coronary artery bypass grafting.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results